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CYTOTOXIC CD8 T CELL IMMUNITY FOR THE TREATMENT OF GENITAL HPV 
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Gloria Sierra, B.S. 
Advisory Professor: Jagannadha K. Sastry, Ph.D. 
ABSTRACT: 
Human Papillomavirus (HPV) induced cancers continue to affect millions of 
women worldwide, with the five year survival rate hovering just under 60% in some 
demographics.  Therefore there is an unmet need to develop effective, yet, easily 
administered therapies to treat established HPV genital lesions.  Even though immune 
checkpoint therapy (ICT) is a promising treatment option in some HPV+ cancers, the 
high cost and associated toxicities are still major concerns for their widespread 
application. HPV cancers are textbook candidates for therapeutic vaccination 
intervention because they’re driven by the expression of viral oncoproteins E6 and E7, 
which serve as ideal tumor specific antigen targets.  An effective therapeutic vaccine 
should be able to overcome tumor mechanisms of immune-evasion and immune-
suppression, while inducing a robust anti-tumor mediated response.   In this dissertation 
I investigated a novel therapeutic HPV peptide vaccination strategy; by incorporating two 
diverse acting adjuvants for induction of strong cytotoxic effector immunity, and utilizing 
the intranasal mucosal route of immunization to ensure efficient trafficking to the genital 
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mucosal tumors.  Overall, I hypothesized that intranasal HPV peptide vaccination 
employing the combination of TLR9 and NKT cell ligands, (CpG-ODN and α-GalCer, 
respectively) will induce potent systemic and mucosal antigen-specific CD8 T cell 
response, specifically at the female reproductive tract (FRT) to eliminate HPV genital 
tumors.   
Utilizing an orthotopic vaginal tumor model in mice, I obtained evidence 
demonstrating the efficacy of the therapeutic HPV peptide vaccine containing α-GalCer 
and CpG-ODN (TVAC), in terms of inducing sustained and efficient tumor regression in 
nearly 85% of treated mice.  The therapeutic efficacy correlated with significant CD8 T 
cell responses and increased ratios of cytotoxic effector to immune suppressive 
populations (regulatory T cells and myeloid derived suppressor cells) in the tumor 
microenvironment.  Treatment with TVAC was also effective against tumors implanted in 
the flank, representing a systemic HPV tumor model.  These results support the feasibility 
and benefits of utilizing intranasally delivered therapeutic vaccines formulated with 
combinations of diverse acting adjuvants, such as the TVAC tested in this investigation, 
as a potential strategy for clinical development to treat established genital HPV tumors.  
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CHAPTER 1. INTRODUCTION  
HPV induced cervical cancers are the second leading cause of death in women 
worldwide.  Despite the availability of preventative vaccines, millions of people who have 
already been exposed to the virus, or are ineligible/unable to receive the vaccine are still 
at risk of developing cancer and requiring treatment.  Therefore there is an unmet need 
for the development of an easily administered therapy for the treatment of HPV induced 
cancers.  HPV driven cancers constitutively express viral gene products (e.g. E6 and E7) 
necessary to induce oncogenic transformation, thereby making them ideal targets for 
treatment using a therapeutic vaccine.   
Therapeutic vaccines are used to boost or modulate the immune response to treat 
existing ailments such as viral infections or cancers [1]; in contrast to prophylactic 
vaccines which offer protection against initial infection [2].  Similar to prophylactic 
vaccines, however, therapeutic vaccines are often made up of two components to induce 
an effective immune response; the first is an immunogen such as a bacterial toxin or 
pathogen-encoded antigen, foreign to the host, the second component is an adjuvant, or 
substance which enhances the body's immune response to the co-administered 
immunogen/antigen [3].  Different classes of adjuvants capable of modulating and 
inducing immune responses in different sets of immune cells are available, and therefore 
the selection of safe yet effective adjuvants is a key aspect for the development of a 
successful vaccine. In addition, therapeutic vaccines must be effective at inducing the 
proper immune response at the site of infection or cancer.  This dissertation investigates 




of a therapeutic peptide vaccine for the treatment of HPV genital tumors.  I also 
investigated different routes of vaccine delivery for determining the most effective 
regimen for therapeutic efficacy against HPV genital cancer.   
In the following chapters, I will first review the role of HPV and other viruses in the 
development of cancer, how HPV, in particular, evades immune recognition permitting 
cancer progression, and the overall burden HPV induced cancers have globally.  I will 
also discuss the various therapeutic approaches that have been developed to treat HPV 
induced cancers, and how the compartmentalization of the mucosal immune system can 
play a role in therapeutic efficacy.  Lastly, I will discuss the main questions and rationale 
of my research.    
1.1 HPV and Cancer 
Cancer is defined by the National Institute of Health (NIH) as a group of diseases 
in which abnormal cells divide without control with the potential to invade nearby tissues.  
They are often categorized by the type of tissue the cancer originates from, and the 
primary site of the disease.  Carcinomas and sarcomas are cancers originating in the 
epithelial layer and supportive/connective tissues of the body, respectively, while 
leukemia and lymphomas are cancers of the bone marrow and glands or lymph nodes.  
A fifth category of cancer classification includes a mixed type of cancer, in which the 
growths are found in multiple categories.   
It is difficult to identify the exact cause of cancer, however, in 1971 Alfred G. 
Knudson formulated the two-hit hypothesis which describes the notion that two “hits” or 




hereditary cancer, retinoblastoma [4].  Although we now know that there are more factors 
at play for the development of cancer, this theory indirectly led to the identification of 
major oncogenes, or genes that, under certain situations, can transform a healthy cell 
into a tumor cell.  The process of cancer transformation not only depends on the mutation 
of tumor suppressor genes, but requires a combination of characteristics termed the 
Hallmarks of Cancer which were describe by Hanahan and Weinberg [5].  These 
hallmarks include self-sufficient growth signals, insensitivity to anti-growth signals, 
evading programmed cell death, limitless replicative potential, sustained angiogenesis, 
tissue invasion and metastasis, deregulated metabolism, and evading the immune 
system.   
Several external or environmental factors have been found to directly increase the 
likelihood of cancer.  These include smoking, tobacco use, poor diet, lack of physical 
activity, exposure to radiation, and infections [6, 7].  In fact, approximately 15% of all 
cancers are caused by viral infections [8, 9].  There are currently seven recognized 
viruses which are known to cause cancer, termed oncogenic viruses.  These viruses and 
their associated cancers are listed in Table 1 [9].  Oncogenic viruses have the capacity 
to prompt unregulated cell replication and uncontrolled growth.  In certain cases, an 
oncogenic virus is able to embed their genetic material into the host genome, allowing 
for the cell’s transformation into cancer.  Although HIV does not directly cause cancer 
and is not listed in this table, it is important to note that, because it causes 
immunodeficiency, it increases the risk of cancer by reducing the body’s ability to fight 




Table 1 Association of viruses and cancer.  The seven known oncogenic viruses 
alongside the type (s) of cancer(s) they are associated with [9].   
ONCOGENIC VIRUS CANCER TYPE 
HUMAN PAPILLOMA VIRUS (HPV) Cervical, Penile, vulvar, vaginal, head and neck 
squamous cell carcinoma (HNSCC) 
EPSTEIN-BARR VIRUS (EBV) Stomach cancers, nasopharyngeal cancers, 
and Burkitt or Hodgkin lymphomas. 
HUMAN HERPES VIRUS 8 (HHV-8) Kaposi Sarcoma, 
HUMAN T LYMPHOTROPIC VIRUS 
TYPE I (HTLV-1) 
Non-hodgkin lymphoma (adult T cell 
leukemia/lymphoma), and lymphocytic 
leukemia 
HEPATITIS B VIRUS (HBV) Liver Cancer 
HEPATITIS C VIRUS (HCV) Liver Cancer, also increases the risk of non-
Hodgkin lymphoma and head and neck 
cancers. 
MERKEL CELL POLYOMA VIRUS 
(MCPYV) 
Merkel cell carcinoma (MCC) 
 
Currently, there are only three FDA approved vaccines for protection against 
these oncogenic viruses.  They include vaccines for the prevention of HBV, HPV, and 
EBV [13].  Despite their availability, however, vaccination rates for each of these viruses 
vary greatly depending on region and among virus [7].   
This dissertation will focus on human papillomavirus (HPV) as it is the most 
common sexually transmitted disease, is responsible for nearly 100% of cervical cancers 
worldwide, 70% of vaginal and vulvar cancers,  60% of penile cancers,  90% of anal 
cancers, and approximately 60-70% of newly diagnosed oropharynx cancers [14].  In the 
next section, the virology and oncogenic mechanisms of HPV will be described, followed 




1.1.1 Virology of HPV 
HPV is an 8kb double-stranded DNA virus containing 8 protein-coding genes.  
There are currently over 200 identified strains of HPV, each having less than 10% 
homology with the rest [15, 16].  The HPV DNA can be categorized into three sections 
based on the genes it encodes or the function it provides: the noncoding upstream 
regulatory region (URR), the early protein coding region which of the virus encodes the 
replication machinery (E1, E2, E4, E5, E6, and E7), and the late protein encoding region 
which encodes the capsid proteins (L1 and L2) [17].  The virus’s replication cycle is 
dependent on the differentiation of the epithelial cells it infects.  Initial infection begins at 
the basal layer of the epithelial layer where the virus gains access to these cells through 
naturally occurring micro-lesions in the epithelia, and begins early gene expression.  The 
expression of E6 and E7 genes helps drive the epithelial cells into the S-phase, creating 
an ideal viral replication environment during host cell proliferation.  As new cells develop 
in the basal epithelia, infected cells move into the upper epithelial layers, where the virus 
begins the production of the late genes required for capsid assembly and eventually 
progeny release [18].  HPV is not a lytic virus, meaning that it does not need to kill, or 
lyse the cell it infects to release its progeny.  It is released when the epithelial cell it 
infects, reaches the top of the epithelium and is shed naturally, avoiding virus-induced 
necrosis and inflammation.  This is one of the many ways HPV is able to remain 
undetected in its host and will be discussed in further detail in the next section [19].   
There are 14 identified oncogenic or “high-risk” strains of HPV.  HPV16 and 




70% of cervical cases around the world [20, 21].  Two of the most common “low-risk 
strains”, which induce genital warts, but do not lead to cancer, are HPV6 and HPV11, 
accounting for over 90% of genital warts cases [22].  It is predicted that over 80% of the 
population has been or will become infected with at least one strain of HPV in their 
lifetime, however, the majority of these cases are asymptomatic and cleared naturally by 
the immune system [18].  When a host becomes infected with what is considered a “high-
risk” HPV strain, and is unable to clear the virus (chronic infection), changes to the virus’s 
genome can lead to integration of the viral genome into the host cell DNA [23, 24]. 
Continuous and overexpression of HPV E6 and E7 are the main drivers of HPV induced 
cancers; as previously mentioned, these proteins are capable of driving the host cell into 
uncontrolled proliferation.  E6 induces the degradation of p53, a tumor-suppressing 
molecule, while E7 binds to and inhibits retinoblastoma (Rb) from binding with E2F, a 
protein, which when is unbound, leads to cell cycle activation and proliferation (Fig. 1) 
[25].  With both of these proteins overexpressed in the host cell, the healthy cells 






Figure 1. HPV E6 and E7 mechanisms of oncogenic transformation.  HPV16 E6 and 
E7 are the main drivers of oncogenic transformation.  E6 is known to bind and degrade 
p53, a major tumor suppressor gene within the host cell, while E7 competitively inhibits 
the binding of pRB and E2F.  By doing so, the unbound E2F protein is able to induce cell 





1.1.2. Mechanisms of HPV immune evasion  
The immune system is a complex network of cells, tissues, and organs that aids 
the body to fight off infections.  It is comprised of the innate and adaptive immune 
systems that work together to control and eliminate pathogens, such as HPV, and can 
also prevent re-infection.  The innate immune system is a rapid, non-specific defense 
mechanism that includes physical barriers such as the skin, defense mechanisms such 
as secretions and mucus, and innate immune cells.  Innate immune cells, including but 
not limited to natural killer (NK) cells, natural killer T (NKT) cells, macrophages and 
dendritic cells (DCs), are capable of recognizing microbial substances through the use 
of pattern recognition receptors (PRRs).  These PRRs, in response to an invading 
pathogen, activate downstream signaling pathways to promote a protective inflammatory 
immune response through the release of cytokines such as IFNγ, TNF-α, and 
granulocyte macrophage colony-stimulating factor (GM-CSF).   
The adaptive immune system is a highly regulated and antigen specific part of the 
immune system that includes B cells and T cells.  While CD4 T cells recognize peptides 
presented on MHC class II and are referred to as “helper T cells”, CD8 T cells recognize 
peptides on MHC class I molecules and are often referred to as cytotoxic T lymphocytes 
(CTLs), as they are able to directly kill infected or cancerous cells.  CD4 helper T cells 
aid in tailoring the immune response to the type of pathogen encountered.  They release 
a multitude of cytokines to either prime B cells for antibody release and pathogen 
neutralization or activate dendritic cells, a type of antigen presenting cell (APC) to 




Dendritic cells are known as the main bridge between the innate and adaptive 
immune systems since they are able to take up, process, and present antigens to the 
adaptive immune cells, inducing antigen-specific immunity.  Dendritic cells require 
stimulatory signals in order to present co-stimulatory molecules required for CD8 T cell 
activation.  These signals can be from inflammatory cytokine responses, or CD4 T cell 
responses [26].   
HPV can avoid both innate and adaptive immunity in approximately 10% of 
infected individuals through several specific mechanisms briefly described here.  Further 
details can be found in the following reviews [27, 28].   
During the initial infection stage, the virus is able to enter the basal epithelial cells 
through naturally occurring micro lesions, and by maintaining low copy numbers, it avoids 
immune detection [27].  As the infected basal cells grow and enter the differentiation 
phase of the epithelium, the virus significantly upregulates viral gene expression and 
DNA replication, wrapping up its replication process as the infected cell reaches its 
terminal differentiation phase at the top of the epithelium, naturally dying and shedding 
the HPV viral progeny as it is released.  By circumventing virus-induced cell death and 
the associated inflammation, HPV is able to avoid triggering the influx of APCs to the 
infection site [27].  Additionally, because HPV is localized to the epithelium, it avoids the 
blood stream and lymphatic system where it can be detected by the host.  Studies also 
indicate that high-risk HPV strains downregulate interferon gene responses necessary 
for antiviral and innate immune response, although this is still not thoroughly understood 




As previously mentioned, approximately 10% of HPV infections with high risk 
strains that remain undetected experience viral mutations and result in oncogenic 
transformation [30].  Failure to induce cellular immunity against infected cells, and viral 
genome integration or deregulation are vital steps that cause HPV infections to lead to 
cancer.  As the cancer progresses, regulatory T cells (Tregs) and Myeloid Derived 
Suppressor Cells (MDSCs) significantly increase within the affected site, abrogating CD8 
T cell responses, and further aiding tumor growth [31].   
1.1.3. Global burden of HPV and promise of a vaccine 
HPV driven cancers make up four percent of total cancer diagnosis every year, 
amounting to a total of almost 700,000 cases, with the majority of patients being women 
diagnosed with cervical cancer [32].  Frequencies and impact of HPV induced cancers 
vary greatly between countries of different economic statuses.  While they make up less 
than three percent of cancer diagnoses in Australia and the United States, they account 
for 26% in sub-Saharan African countries [33].  Even within the United States, economic 
and racial disparities depict a correlation with those who are diagnosed with HPV cervical 
cancer [34].  Studies indicate that a lack of regular screenings, access to affordable 
medical care, and vaccination rates contribute to these disparities in the US and around 
the world [33, 35].   
The prophylactic vaccine Gardacil9 is currently offered and approved for the 
prevention of HPV infection, significantly reducing the risk of HPV-induced cancers by 




protecting women against cervical cancer, but because HPV infects and is transmitted 
by men and women, it is now recommended that both males and females of adolescent 
age be vaccinated against HPV in order to reduce transmission and protect against 
cervical, penile, anal, vaginal, vulvar, and oral cancers [36, 38-40].  The Gardacil9 
vaccine is composed of virus-like particles (VLPs) corresponding to the major capsid 
proteins on the surface of the virus, L1, which are immunogenic on their own.  It induces 
immunity and provides protection against the seven most common oncogenic HPV 
strains, HPV16, 18, 31, 33, 45, 52 and 58, plus the two strains responsible for genital 
warts, HPV 6 and 11 [41].  Admixed with aluminum salts, amorphous aluminum 
hydroxyphosphate sulfate (AAHS), studies indicate that even just a single dose is 
sufficient to significantly reduce the risk of cancer [42, 43].   
Despite the vaccine’s availability, global HPV infections remain high.  Originally 
released in 2006, delays in vaccine uptake and availability rendered millions of adults 
ineligible for the vaccine because it is not recommended for those with preexisting 
infections.   
The current standard of care for patients diagnosed with cervical cancer varies 
depending on the severity and spread of the disease but typically involves the surgical 
removal of the affected area plus a combination of either chemotherapy or radiation 
therapy.  This approach often comes with toxic side effects, lowering the quality of life for 
affected individuals [44-46].  In addition, the overall five year survival rate of women 
treated for cervical cancer is still less than 60% in some demographics [21].  Therefore, 




administered treatment options for HPV induced cancers without the use of 
chemotherapy and radiation therapy.   
1.1.2. Therapeutic alternatives for HPV induced cancers 
Over the years, various approaches have been taken to treat HPV-induced 
cancers, with the overall goal of shifting away from chemotherapy and radiation therapy.  
In the following section I will briefly describe some of these methods including checkpoint 
inhibitors, cell based vaccines and therapeutic vaccines.  It is important to reiterate that 
the currently available prophylactic vaccine described in the preceding section is not an 
effective treatment for existing HPV infections, as it only protects against initial infection.  
As previously mentioned, the prophylactic vaccine induces immunity against the surface 
proteins of the virus, allowing it to neutralize the virus prior to entering and infecting the 
host cell [21, 36].  These late genes encoding the surface proteins, along with a portion 
of the early genes are often lost during viral DNA integration into the host genome [23, 
24].  Therefore, the majority of the following therapeutic approaches focus on inducing 
or enhancing cellular immunity against HPV proteins E6 and E7 as they are the primary 
drivers of cell transformation and cancer.  In addition, these proteins are constitutively 
expressed in HPV induced cancers, and targeting these virus-specific proteins avoids 
off-target effects.  Recent studies have also identified the constitutive expression of the 
E5 protein in a large percentage of cancers, signifying that it could serve as a third 




One promising method of enhancing cellular immunity for the treatment of HPV 
induced cancers is the use of checkpoint inhibitors.  Studies indicate that patients 
progressing from early stage HPV disease to higher grades express increased levels of 
PD-1 and PDL-1 on the infiltrating T cells and DCs, significantly dampening the anti-
tumor immune response [48].  Utilization of checkpoint inhibitors to block these 
dampening functions of PD-1 and PDL-1, allows the infiltrating CD8 T cells to continue 
killing infected cells [49].  Many ongoing clinical trials are testing the potential of these 
and other checkpoint inhibitors such as CTLA-4, alone and in combination with traditional 
HPV therapies and are listed in detail in the following review [50].   
In addition, cell-based therapies for treatment of advanced and non-responding 
cancers have also been receiving growing interest.  Cell therapies include adoptive T cell 
transfer, dendritic-cell vaccines, CAR-T cell therapies, and treatment with engineered 
TCR T cells.  These methods all involve the isolation of cells of interest, such as dendritic 
cells or T cells from a patient, performing ex-vivo manipulations to increase therapeutic 
potential, and infusing these cells back into the same patient.   
For example, DCs pulsed with recombinant HPV proteins, stimulated ex vivo and 
transferred into cervical cancer patients increase antigen specific immunity in the blood 
[51-53].  Although this method showed efficacy for inducing CTL response systemically, 
a clinical response was not observed [52].   
A more direct approach involves the isolation of tumor infiltrating lymphocytes 
(TILs) from cervical cancer patients, and clonally expanding those specific to the patient’s 




antigen specificity.  This method is a highly personalized form of medical treatment and 
has shown great clinical response in patients [54, 55].   
While these therapies are currently used in clinics and have shown promising 
results, they are often very time consuming and costly.    In the following chapter, I will 
describe the multiple types of therapeutic vaccines that have been developed and 
proposed for HPV induced cancers, while including few examples that have been tested 
in clinical trials.   
1.2. Therapeutic Vaccines 
Therapeutic vaccines are designed to boost or modulate immune response to 
treat existing ailments such as viral infections or cancers, in contrast to prophylactic 
vaccines which offer protection against initial infection [2].  Several types of therapeutic 
vaccines have been developed for the treatment of HPV induced cancers.  These 
vaccines, as previously mentioned are aimed at inducing cellular immunity against the 
HPV proteins E6 and E7 as they are the main drivers of oncogenic transformation.  One 
major distinction between these therapeutic approaches is in the antigen formulation 
used.  These include the use of viral vectors, proteins, peptides, and DNA for the delivery 
of antigens.  The following section will describe each of these approaches along with 
some examples and benefits and disadvantages of each.   
1.2.1. Live vector based vaccines 
Viral and bacterial vector based vaccines utilize recombinant vectors encoding 




Once within the cell, viral and bacterial vectors are able to produce the target antigens 
or peptides, promoting antigen presentation.  In order to increase immunogenicity of this 
approach and ensure the infected cell is recognized by the immune system, the vectors 
typically also encode stimulatory factors such as IL-2 [56, 57] or pathogen associated 
molecular patterns (PAMPs) [58].  Upon successful infection and translation of the 
encoded antigens, the vector activates downstream sequence of events, inducing an 
inflammatory response against the target antigen.   
One approach, utilizing live attenuated Listeria monocytogenes encoding HPV16 
E7 protein linked to listeriolysin O (TG4001) showed promising pre-clinical results, 
however, clinical safety and efficacy are still undergoing in cervical cancer patients with 
recurring disease [56].  Another group utilized a modified vaccinia virus Ankara vector 
for the production of E6 or E7 proteins of HPV along with IL-2, which has shown success 
in inducing antigen specific CD8 T cell responses in patients [56].   Additionally, vaccinia 
vectors, adenovirus vectors, and semliki forest virus vectors have also been used for the 
development of therapeutic HPV vaccine candidates [56, 59, 60].   
Although effective measures are taken to ensure safety profile of these vaccines, 
utilizing live viral vectors continues to pose safety concerns as the risk of DNA mutation, 
integration and pathogenic potential in immunocompromised patients is a genuine risk 
.[61]  In addition, because live attenuated viruses are also slightly immunogenic, there is 
the possibility of the patient’s immune system recognizing the viral antigen and inducing 




1.2.2 Protein and peptide based vaccines 
Protein and peptide based vaccines have long been proposed for the treatment 
of HPV induced cancers [63].  This approach consist of delivering recombinant proteins 
or peptides from HPV to be taken up, processed and presented by DCs, inducing an 
antigen specific CD8 T cell response.  Interests remain high in these categories, in 
particular peptide based vaccines, due to the low cost of production, long term stability, 
and high safety profiles.  This approach does not carry concerns associated with the use 
of vector or DNA based vaccines, however, they do require the use of adjuvants due to 
low immunogenicity.  Co-administration with adjuvants such as chemokines, toll-like 
receptor ligands, or lipids have shown to increase immunity against these peptide, 
resulting in enhanced CD8 T cell responses [63].  One hurdle of utilizing peptides for 
immune induction is the specificity of different epitopes to MHC types.  Not all peptides 
have high affinity or compatibility to certain MHC types, therefore depending on the 
peptides of choice, these vaccines can be specific to different HLA haplotypes.  One 
method to circumvent this is the use of long overlapping peptides covering the entire 
protein sequence.  This ensures complete coverage of the proteins of choice while 
avoiding oncogenic risks of delivering the entire protein.  Additionally, whole protein 
administration typically results in longer peptide presentation on MHC class II molecules, 
shifting the immune response towards a CD4 T helper immune response [64].  A 
Synthetic Long Peptide (SLP) vaccine which utilizes HPV16 E6 and E7 peptides co-
administered subcutaneously with Montanide ISA-51 adjuvant is currently in clinical trials 




1.2.3. DNA vaccines 
DNA and RNA based vaccines are another emerging field of interest as they utilize 
genetic material with the capability to produce full-length protein or peptides, allowing for 
natural processing and presentation by APCs[66].  Precautions and modifications to the 
full-length protein approach must be taken, however, to prevent the risk of causing 
cellular transformation [67].  DNA and RNA constructs are economically feasible for large 
scale production, but DNA holds better stability than RNA [68].  DNA vaccines are poorly 
immunogenic and require the use of adjvuants, similar to protein and peptide vaccines 
[68].   
One example of a DNA vaccine encoding a full-length protein construct shuffled 
the gene sequence of HPV E6 and E7 in a way that disabled the oncogenic potential of 
translated proteins, but still allowed for processing of the proteins and proper epitope 
presentation for efficient E6 and E7 induced immunity [69].  Although this approach has 
proven to induce robust immunity even in pre-clinical models, clinical outcome was not 
as robust as anticipated [70].   
1.2.4. Genome editing 
The latest approach and last one that will be covered in this chapter is the use of 
genome editing tools to reduce the expression of the driving oncogenes.  Pre-clinical 
models in vitro and in vivo have shown the power of using the CRISPR/Cas9 genome 
editing system in order to cleave the HPV16/18 E7 oncogene embedded in the host DNA, 




Because primary HPV lesions are found at mucosal sites, it’s important but often 
overlooked, for a therapeutic vaccine to induce an immune response at these locations.  
Many pre-clinical studies are tested against subcutaneously implanted HPV gene 
expressing tumor models and show promising results, however, lack investigations 
focusing on immune induction in the genital mucosa [73-76].  A more thorough 
understanding of the mucosal immune system can benefit the advancement of 
therapeutic HPV vaccines.   
1.3. Mucosal immunology and Vaccines 
The majority of HPV induced cancers are localized to the genital mucosa, with an 
increasing percentage occurring in the oral mucosa.  Therefore, therapeutic efforts must 
ensure not only a robust immune response, but also proficient cellular immunity at the 
genital tract, or female reproductive tract (FRT).  As previously mentioned, the oncogenic 
proteins of HPV E6 and E7 are the primary targets of therapeutic vaccine approaches.  
Although several strategies have proven effective for the induction of a cellular immune 
response against these antigens, clinical outcome has not reflected pre-clinical 
expectations.  Increasing tumor infiltration is a current challenge facing many of the 
previously described vaccination approaches.  In the following section I will describe the 
compartmentalization of the mucosal immune system and prospective benefits of 




1.3.1. Compartmentalization of the Mucosal Immune system 
The mucosal immune system is a highly compartmentalized portion of the overall 
immune system.  It functions independently from the systemic immune system and is 
responsible for discriminating harmful pathogen encountered from non-pathogenic or 
commensal bacteria at the mucosal membranes throughout the body [77, 78].  It consists 
of the gastrointestinal, genital, and respiratory tracts which are constantly being exposed 
to foreign microbes through the functions of gas exchange, nutrient absorption and 
reproduction, therefore the overall nature of the mucosal immune system is highly 
tolerogenic, avoiding unnecessary inflammatory immune responses to commensal 
bacteria and nutrients.  Despite the tolerogenic nature of the mucosal immune system, 
the mucosal epithelial layers are lined with what is an equivalent to the systemic lymph 
nodes specific for mucosal immunity [78].  The Mucosal-associated lymphoid tissues 
(MALT) are situated adjacent to mucosal tissues and make up a complex network of 
lymphoid structures similar to lymph nodes of their corresponding mucosal tissue [79].  
They are classified into several compartments including the Gut-Associated Lymphoid 
Tissues (GALT), the nasopharynx-associated lymphoid tissues (NALT), the conjunctiva-
associated lymphoid tissue (CALT), the vaginal associated lymphoid tissue (VALT), and 
the bronchus-associated lymphoid tissues (BALT).  Presence of these structures can 
vary between species, however, their functions are similar, and are the sites where 
antigen-specific immune responses are initiated.  Each of these components make up 
portions of the common mucosal immune system, which is able to induce immune 




have found that the route for mucosal immunization can heavily influence the resulting 
immune response [81-83].  Oral, vaginal, rectal, and nasal vaccinations have all been 
investigated and will be briefly discussed below.   
Currently, there are only six mucosal vaccines approved for human use targeting 
the prevention of the following infections; cholera, rotavirus, salmonella, and influenza.  
All are administered orally except for Flumist®, which protects against influenza and is 
the only intranasal vaccine currently available for human use [84].  The once orally 
administered polio vaccine that aided in the eradication of the disease in the United 
States is no longer commercially available after a handful of cases reporting the live 
attenuated virus reverting its virulence and causing vaccine-associated paralytic 
poliomyelitis [85].  Protection against polio is now achieved through the intramuscular 
immunization using an inactivated polio vaccine (IPV), eliminating the risk of utilizing a 
live virus for immunization.   
The ease and non-invasive nature of oral and nasal vaccine administration make 
these routes attractive for mass-scale vaccination, however, route selection depends on 
intended immune outcome.  While oral immunizations have the capacity to induce 
immunity at the oral tissues and gastrointestinal tract, nasal immunizations have been 
shown to induce immunity in the nasal tissues, respiratory tract, and interestingly, studies 
have demonstrated immune response at the female reproductive tract (FRT) after 
intranasal vaccinations [86].  Vaginal and rectal vaccinations induce less disseminated 
responses but are capable of inducing immunity at the genital tissues and gut, 




immunity, the reverse is not always true.  Intraperitoneal vaccinations repeatedly failed 
to induce any mucosal immune response [87-89].  These characteristics are important 
to note when developing drugs to combat infections like HPV which reside primarily in 
the mucosal microenvironment.   
One of the benefits of utilizing the mucosal route of immunization is mucosal 
imprinting.  Mucosal imprinting refers to the ability of mucosally derived DCs to induce 
upregulation of mucosal-specific homing receptors on activated T cells.  Studies show 
that mucosal DCs derived from the lung or gut, are able to induce upregulation of related 
integrin and homing receptors such as CD49a and α4β7, respectively [90, 91], therefore 
mitigating the localization of the resulting immune responses.  Imprinting mechanisms 
been investigated for various immunization routes, but the majority of detailed studies 
have been on GALT and gut-homing mechanisms.  It’s been shown that GALT DCs, 
specifically CD103+ DCs from the lamina propria are the only cells able to generate gut-
tropic CD8+ effector cells in vitro.  This indicates that the priming APC is the primary factor 
responsible for mucosal imprinting, and not so much the location of the priming [91].   
1.3.3. Mucosal Adjuvants 
Similar to systemically delivered vaccines such as intramuscular or subcutaneous 
vaccines, immune response is greatly enhanced with the use of adjuvants.  Mucosal 
adjuvants have historically been non-toxic derivatives of bacterial toxins such as cholera 
toxin (CT), bacterial DNA, virus like particles, and cytokines/chemokines.  Although all 




commonly used derivative of heat-labile enterotoxin (LT), for example proved to be toxic 
in humans when used in clinical studies [92].  In another instance, administration of CT 
via the intranasal route showed evidence of it trafficking into the brain, therefore also 
deemed unsafe [93].   
Bacterial DNA such as CpG-ODN, has however shown successes in clinical trials 
when delivered intranasally and orally with no apparent toxicities [94].  CpG-ODN is a 
TLR9 agonist, and is capable of inducing APC activation, increasing CD80/86 levels, and 
skewing immunity towards a CD8 mediated response [94, 95].  Monophosphoryl lipid A 
(MPL) is another TLR agonist that binds to TLR4 on APCs and has recently been 
approved by the FDA for intramuscular immunization of the prophylactic vaccine against 
HPV infections-Cervarix [96].  Several pre-clinical trials which contain MPL have resulted 
in robust immune responses when delivered intranasally [97].  A more thorough review 
of mucosal adjuvants and their use in clinical trials can be found here [98, 99] 
1.3.4. α-GalCer as a mucosal adjuvant 
α-Galactosylceramide (ɑ-GalCer), a NKT cell ligand which was originally derived 
from a marine sponge, has shown great use as a potent NKT cell agonist.  It is taken up 
by APCs, and presented on CD1d molecules, inducing the rapid activation of NKT cells.  
This activation results in a rapid and robust release of pro-inflammatory cytokines 
including IFN-ɣ, IL-2, and IL-4, which in turn causes activation of NK cells, CD8 cells, B 
cells, and DCs [100, 101].  Although α-GalCer has been deemed safe in the clinics, one 




administration [102, 103].  Our lab, and others, has shown evidence that mucosal 
administration in the form of intranasal or oral delivery of α-GalCer circumvents NKT cell 
anergy, allowing for repeated activation and a stronger induced immune response 
against co-administered antigens [104-107].  Although systemic administration of α-
GalCer showed a good safety profile in humans, mucosal route of administration has yet 
to be tested in [108].  Nonetheless, interests in its use for anti-tumor efficacy remains 
high.  Multiple adjuvant related studies have shown enhanced immunity, and sometimes 
even synergistic increases of immune response after the use of α-GalCer in combination 
with a second adjuvant.  In particular, several studies have shown that α-GalCer 
combined with a TLR agonist results in significantly higher DC activation, cytokine 
release and overall immunity [109-111].  An example in our own lab, showed that 
mucosal immunization with the combination of TLR-9 and α-GalCer is able to induce 
robust antibody mediated immunity against HIV proteins [105].  Because of the robust 
potential of α-GalCer and CpG-ODN as therapeutic adjuvants, I set out to investigate 
whether mucosal intranasal administration of these two adjuvants harbored enhanced 
therapeutic potential against HPV genital tumors.   
Utilizing an orthotopic HPV vaginal tumor model, I tested the therapeutic potential 






CHAPTER 2: HYPOTHESIS AND SPECIFIC AIMS 
 Understanding how route of vaccination and adjuvants interact with one another 
is critical for the development of a successful therapeutic vaccine.  Despite the availability 
of prophylactic vaccines against HPV, thousands of people who are ineligible/unable to 
receive the vaccine are still at risk for HPV induced cancers.  Therefore, there is still a 
need to develop safe, yet effective treatment strategies that are not only easily 
distributed, but are also cost-effective.  Based on the reasons described in the previous 
chapter, this dissertation investigates the potential of an intranasal therapeutic HPV 
peptide vaccine employing the combination of adjuvants (α-GalCer and CpG-ODN) for 
the treatment of HPV genital tumors.  The peptides chosen for this vaccine were originally 
identified in a study from our lab which realized that immune memory to these select 
peptides correlated with recurrence free survival in women treated for cervical neoplasia 
[112].  They include HPV16 Q19D (E744–62, QAEPDRAHVYNIVTFCCKCD); R9F (E749–
57, RAHVYNIVTF); Q15 L (E643–57, QLLRREVYDFAFRDL); and V10 C (E649–58, 
VYDFAFRDLC). 
Therefore, I set out to investigate the following hypothesis:  
Intranasal vaccination employing the combination of TLR9 and NKT cell ligands, (CpG-
ODN and α-GalCer) will induce potent systemic and mucosal antigen-specific CD8 T cell 
immunity, specifically at the female reproductive tract (FRT) to eliminate HPV genital 




• Aim 1: Test whether intranasal vaccination employing the combination of 
adjuvants, relative to each adjuvant alone, will induce strong CD8 T cell response 
to the co-administered antigen at multiple systemic and mucosal tissues  
• Aim 2: Determine whether intranasal delivery of HPV peptides together with the 
adjuvant combination will be effective in treating established HPV+ vaginal 
tumors. 
• Aim 3: Investigate whether the tumor location and route of vaccination will 





CHAPTER 3. MATERIALS AND METHODS 
3.1 Animals  
Female C57BL/6J mice (6–10 weeks) were purchased from the Jackson 
Laboratories (Bar Harbor, ME, USA) and were maintained in a pathogen-free 
environment at the institutional animal facility accredited by the Association for 
Assessment and Accreditation of Laboratory Animals Care International. Animals were 
anesthetized with isoflurane for blood draws and hormonal administration, and with a 
mixture of ketamine (100 mg/kg) and xylazine (10 mg/kg) administered by intraperitoneal 
(IP) route for tumor implantation and N9 Treatment. All animal procedures were 
conducted, including euthanasia in compliance with the University of Texas MD 
Anderson Cancer Center Institutional Animal Care and Use Committee (IACUC) 
guidelines (Project ID: 00000858-RN02).   
 
3.2 Cell Line and Reagents  
The TC-1-luciferase (TC-1–Luc) tumor cell line is of lung fibroblast origin from 
C57BL/6 mice that was transfected to stably express the E6 and E7 oncogenes of HPV-
16 as well as the H-Ras oncogene. This cell line additionally expresses firefly luciferase. 
This cell line was a kind gift from Drs. T.-C. Wu and C. Hung (Johns Hopkins School of 
Medicine, Baltimore, MD, USA). Cells were maintained in RPMI 1640 medium 
supplemented with 10% heat inactivated FBS, 50 units/mL of penicillin–streptomycin, 




The four vaccine peptides Q19D (E744–62, QAEPDRAHVYNIVTFCCKCD); R9F 
(E749–57, RAHVYNIVTF); Q15 L (E643–57, QLLRREVYDFAFRDL); and V10 C (E649–58, 
VYDFAFRDLC), were purchased from Elim Biopharma (Hayward, CA, USA). Stock 
solutions were prepared in a mixture of 10% dimethyl sulfoxide (DMSO) and 90% 1 × 
PBS at a concentration of 10 mg/mL. The α-GalCer adjuvant was purchased from 
DiagnoCine (Hackensack, NJ, USA) and dissolved in DMSO (Sigma, St. Louis, MO, 
USA) to prepare a stock solution at a concentration of 1 mg/mL. The CpG-ODN 1826 
adjuvant was obtained from InvivoGen (San Diego, CA, USA) and dissolved in sterile 
endotoxin free water to prepare a stock solution at a concentration of 10 mg/mL. 
Endotoxin-free ovalbumin (OVA) protein was purchased from InvivoGen (San Diego, CA, 
USA) and reconstituted at 20 mg/mL in PBS. Anti-CD8 blocking antibody was purchased 
from BioXCell (Lebanon, NH, USA). The α4–1BB monoclonal antibody (LOB12.3) with 
<1 endotoxin unit/mg was purchased from BioXcell (Lebanon, NH, USA) and 
administered three times (350 µg/dose) via IP route on days 5, 8, and 11 after tumor 
implantation as previously described [11]. The APC-labeled tetramer of H-2 Db-restricted 
CD8 T cell epitope peptide R9F from the E7 oncoprotein of HPV-16, (E749–57, 
RAHYNIVTF) was procured from the MHC tetramer production facility at Baylor College 
of Medicine (Houston, TX) and was used for the detection and analysis of HPV antigen-
specific CD8 T cell responses in different tissues by flow cytometry.  
The estradiol was obtained by Sigma and diluted to a stock concentration of 
1mg/ml in peanut oil (Sigma) by first dissolving 20mg estradiol in 1ml of 100% ethanol 




was obtained from TCI and was used at a 10mg/mL solution in PBS.  Nonoxyl-9 was 
obtained from Abcam and stored in a de-humidifier chamber at room temperature.     
 
3.3 In Vivo Tumor Experiments  
For vaginal tumor experiments, female C57BL/6J mice (6–10 weeks) were first 
hormonally synchronized by administering 0.1µg estradiol in peanut oil and 2mg 
Medroxyprogesterone acetate (DepoProvera) in PBS subcutaneously on two 
consecutive days (Fig. 2).  One week later, cytology of vaginal smears was analyzed to 
ensure mice were in diestrus as described by Decrausaz et al [113].  On the same 
evening after collecting cytology samples, 20µL of 10% Nonoxyl-9 (N-9) was instilled in 
the vaginal cavity of mice anesthetized with the ketamine/xylazine mixture and were left 
over night.  The following morning, each mouse was again anesthetized with 
ketamine/xylazine mixture and the vaginal cavity was washed five times with 80µL PBS 
for the removal of all N-9.  After washes were complete, 2 × 104 TC-1-Luc cells in sterile 
PBS were instilled in the vaginal tract.  Mice are kept in the supine position with their 
lower halves slightly raised until anesthesia wears off.  Treatment with N-9 induces micro-
lesions in the vaginal epithelial walls, mimicking the naturally occurring micro-lesions in 
humans necessary for HPV to access and infect basal epithelial cells.  In this vaginal 
tumor model, the micro-lesions generated provide an anchoring surface for the tumor 
cells to embed within the vaginal epithelia.  Tumor growth was monitored semiweekly 
using Xenogen In Vivo Imaging System (IVIS) and expressed as average luminescent 




For the experiments testing the flank tumor model, 2x105 TC-1 cells in sterile PBS 
were injected subcutaneously in the left dorsal flank.  Tumor size (length x width) was 
measured 3 times per week using calipers and reported as tumor area (mm2).   
 
Fig. 2. Vaginal tumor implantation and vaccination scheme.  Mice are 
hormonally synchronized one week prior to tumor implantation, on days -8 and -7 by 
administering Estradiole and Depo-provera subcutaneously 24 hours apart.  One day 
prior to tumor implantation vaginal washes are collected to ensure diestrus 
synchronization and treated with 10% nonoxyl-9, overnight.  The next morning, on day 
0, the vaginal cavities are washed multiple times to remove the N-9, and 20,000 TC-1 
Luc cells are then instilled into the vaginal cavity.  Mice are immunized on days 5 and 11 
after tumor implantation, and after successful tumor implantation has been confirmed, 
and imaged weekly.    
 
3.4 Vaccination Treatment  
For intranasal vaccinations, five mice at a time were put under ketamine/xylazine 
anesthesia and were maintained in the supine position while the listed doses of HPV 




combination of both adjuvants were carefully administered in a drop-wise fashion using 
a micropipette as previously described [114, 115].  More specifically, the total volume of 
each vaccine (41ul for TVC, 42ul for TVA, and 43ul for TVAC) was divided into four doses 
(ranging from 10.25ul for TVC to 10.75ul for TVAC) and each dose was administered in 
a slow, dropwise fashion to each of the five mice, this allowed each mouse to rest in 
between doses.  Vaccinations were administered on days 5 and 11 post-tumor 
implantation.  For vaginal tumor-bearing mice, tumor size was first assessed by 
luciferase imaging on day 5 to ensure successful tumor formation, and tumor bearing 
mice were grouped according to tumor size in order to obtain similar average starting 
tumor size per treatment.  Mice with a starting tumor size exceeding 20,000 ROI 
(p/sec/cm2/sr) were evaluated separately and are referred to as “large vaginal tumors” in 
the results section. 
 
3.5 Isolation of Lymphocytes 
For isolation and characterization of vaginal and flank tumor infiltrating 
lymphocytes (TIL), mice were implanted with 3 × 104 TC-1–Luc cells in 10 µL, and 30x104 
TC-1-Luc cells in 200µL of PBS/Matrigel mixture, respectively, at a 2:1 ratio for the 
analyses of tumor-infiltrating leucocytes (TIL). Based on the prior survival analyses of 
the different treatments/vaccinations, one week after the second vaccination was 
selected as the time point to sacrifice mice for the TIL analyses studies. After CO2-based 
euthanasia, each tumor was collected and diced into < ½ cm pieces and digested in a 




passed through a 45 µm strainer. Lymphocytes were enriched through discontinuous 
percoll gradient centrifugation and stained for flow cytometry analysis as previously 
described [114, 116].   
For isolation and characterization of lymphocytes from the female reproductive 
tract (FRT), the vagina, uterus, and uterine horns were collected and cut into small 
pieces. Diced tissue was then incubated in 5 mM EDTA for one hour, followed by 
digestion with collagenase D (1 mg/mL) for 1h at 37 °C. Tissues were then passed 
through a 45 µm strainer and purified by discontinuous percoll gradient centrifugation 
[117].  
Lastly, for isolation of lymphocytes from other lymphoid organs, including spleen, 
CLN, ILN, these soft tissues were directly passed through a 45um strainer.  Splenocytes 
were pelleted and treated with red blood cell (RBC) lysis solution (ACK from Thermo 
Fisher) for one minute before being washed with and re-suspended in cell media.   
 
3.6 CD8 Depletion  
For in vivo CD8 depletion, mice were administered 100 µg of aCD8 mAb from 
BioXCell (Lebanon, NH, USA) via the intraperitoneal (IP) route one day prior to the first 
vaccination dose, and every three days after that until the completion of the experiment. 
The CD8 depletion was monitored in the blood throughout the course of the experiment 





3.7 NK Depletion  
For in vivo NK cell depletion, mice were administered 200 µg of PK136 mAb from 
BioXCell (Lebanon, NH, USA) via the intraperitoneal (IP) route one day prior to the first 
vaccination, and once every week until the completion of the experiment.  Proper 
depletion of NK cells was monitored in the blood throughout the course of the experiment 
as described in the results section.   
 
3.8 Adoptive Transfer of OT-I Cells  
The ovalbumin (OVA)-specific OT-I TCR transgenic (Tg) CD8 T cells were 
obtained from lymph nodes of untreated OT-I mice (CD45.1+) and 1 × 106 cells were 
transferred to congenic C57BL/6J mice (CD45.2+) intravenously in 200 µL of sterile PBS. 
Mice were immunized intranasally with 5 µL of reconstituted endotoxin free OVA alone 
or in the presence of α-GalCer and/or CpG-ODN adjuvants one day after adoptive 
transfer and sacrificed one week after vaccination.  
 
3.9 Flow Cytometry Analysis 
Single cell suspensions from tumors, tissues or PBMC were fixed using the 
Foxp3/Transcription Factor Staining Buffer Set (eBioscience, San Diego, CA, USA) and 
then stained with antibodies to different surface and intracellular markers obtained from 
Biolegend (San Diego, CA, USA), BD Biosciences (Franklin Lakes, NJ, USA), 
eBioscience (San Diego, CA, USA), and Life Technologies (Carlsbad, CA, USA). The 




at Emory University (Atlanta, GA, USA). Flow cytometry data were collected on a five-
laser, BD Biosciences LSR II cytometer and analyzed using FlowJoTM Software for 
Windows, version 10 (Becton, Dickinson and Company, Ashland, OR, USA).  
 
 
3.10 Statistical Analysis  
All statistical analyses were performed using Graphpad Prism version 8 for 
Windows. Statistical significance was determined using either ordinary one-way ANOVA 
plus multiple comparisons, or the Brown–Forsythe and Welch ANOVA plus multiple 
comparisons to test for differences between groups. Statistical significance for survival 
analysis was calculated using the Mantel–Cox log rank test where indicated.  p value of 
<0.05 was considered significant in each comparison. All figures depict average data 





CHAPTER 4. RESULTS 
4.1. Introduction:  
We previously reported that in the TC-1 luc preclinical HPV vaginal tumor model, 
therapeutic vaccination with synthetic peptides corresponding to the E6 and E7 
oncoproteins of HPV-16 and α-GalCer adjuvant delivered by the intranasal route in mice, 
reduced tumor growth rate but required α4–1BB antibody immunotherapy to induce 
sustained tumor regression and significant survival advantage [114].  The anti-tumor 
efficacy from this combination of intranasal vaccination and immunotherapy correlated 
with the induction of highly cytotoxic CD8 T cells expressing multiple granzyme effector 
molecules. 
Toxic side effects and the high costs associated with immunotherapy, however, 
are concerns with this treatment approach [118-120]. Therefore, I tested an alternate 
strategy for effective induction of antigen-specific CD8 T cell response by incorporating 
the toll-like receptor (TLR) 9 ligand CpG-ODN along with α-GalCer, as diverse acting, 
but clinically relevant adjuvants.  
The rationale for the adjuvant selection is that α-GalCer adjuvant activates antigen 
presenting cells (APCs) through the stimulation of NKT cells, resulting in the release of 
cytokines such as IFN-γ and IL-2 which act back on the APCs, inducing maturation and 
increasing antigen presentation [121].  Meanwhile CpG-ODN directly stimulates APCs 
by binding to TLR-9 present on the cell surface, inducing antigen-specific CD8 T cell 
immunity [122].  These two activation mechanisms recognized as alternative (NKT-




activate distinct chemokine signaling to recruit diverse sets of naïve CD8 T cells for 
enhanced adaptive immunity [26].   
I hypothesized that intranasal vaccination employing the combination of TLR9 and 
NKT cell ligands, (CpG-ODN and α-GalCer) will induce potent systemic and mucosal 
antigen-specific CD8 T cell immunity, specifically at the female reproductive tract (FRT) 
to eliminate HPV genital tumors.   
In order to test this hypothesis, I developed the following aims:  
• Aim 1: Test whether intranasal vaccination employing the combination of 
adjuvants, relative to each adjuvant alone, will induce strong CD8 T cell response 
to the co-administered antigen at multiple systemic and mucosal tissues  
• Aim 2: Determine whether intranasal delivery of HPV peptides together with the 
adjuvant combination will be effective in treating established HPV+ vaginal 
tumors. 
• Aim 3: Investigate whether the tumor location and route of vaccination will 
influence therapeutic efficacy of the HPV peptide vaccine.   
4.2: (Aim 1) Test whether intranasal vaccination employing the combination of 
adjuvants, relative to each adjuvant alone, will induce strong CD8 T cell response 
to the co-administered antigen at multiple systemic and mucosal tissues  
In this section, I first addressed the hypothesis that intranasal vaccination utilizing 
the combination of α-GalCer with CpG-ODN, relative to each adjuvant alone, will result 
in higher induction of CD8 T cells specific to the co-administered antigen at multiple 




hypothesis that the resulting CD8 immune response will exhibit stronger cytolytic 
characteristics in mice receiving the combination of adjuvants in comparison with either 
adjuvant alone.   
Data obtained from these studies were included in recently published manuscript 
(Seirra et al. 2020) 
4.2.1 Determine the potential of the intranasal vaccination using α-GalCer and/or CpG-
ODN adjuvants for promoting trafficking of CD8 T cells to the FRT (Aim 1.1) 
In order to determine whether the proposed intranasal therapeutic peptide 
vaccination strategy will be effective to treat established HPV genital tumors, I first tested 
for successful induction of cellular immunity to the FRT.  Specifically, I investigated 
whether vaccination using the combination of adjuvants, relative to each adjuvant 
individually, will increase CD8 T cell responses at the FRT, in particular antigen specific 
CD8 T cells.  For this, I have adapted the ovalbumin (OVA)-specific OT-I TCR transgenic 
(Tg) CD8 T cells as a model system because of the convenience and efficiency to monitor 
induction and localization at multiple tissue sites.   
In this approach, mice were adoptively transferred with 1x106 OT-I cells 
intravenously one day prior to intranasal administration of endotoxin-free ovalbumin 
(OVA) alone or along with α-GalCer, or CpG-ODN, or the combination of α-GalCer and 
CpG-ODN.  Mice were sacrificed one week after for flow cytometry analysis of isolated 
lymphocytes from the spleen, and FRT along with vaccine-draining cervical lymph nodes 




percentages of OT-I cells (CD45.2+ and Va2+) in each of the different groups of mice and 
clearly establishes the effectiveness of the vaccine containing the two adjuvants, α-
GalCer and CpG-ODN, together verses each adjuvant alone in terms of significantly 
higher percentage of OT-I cells in each of the tissues analyzed.   
These data demonstrate that intranasal immunization with OVA using either α-
GalCer or CpG-ODN increased the percentage of OT-1 cell in the spleen, cervical lymph 
nodes (CLN), inguinal lymph nodes (ILN) and the female reproductive tract (FRT) when 
compared to mice receiving OVA alone.  Immunization using the combination of 
adjuvants further increased the percentages of OT-I cells significantly, in all the tissues 








Figure 3. Intranasal immunization utilizing the combination of α-GalCer and CpG-
ODN adjuvants induces significant increase of antigen specific CD8 T cells in 
systemic and mucosal tissues.  Adoptively transferred OT-I cells were analyzed by 
flow cytometry in spleen, FRT, CLN, and ILN one week after intranasal immunization 
with OVA alone or in combination with α-GalCer and CpG-ODN adjuvants individually or 
together. Representative gating strategy from the spleen is shown (A); OT-I cells are 
gated from CD8+ cells as double positive for CD45.1 and Vα2 (left panels of B-E).  
Representative flow plots of OT-1 cells in each tissue are shown in B-E (left panels of B-
E), and average values for the frequencies in each tissue are summarized in the bar 
graphs in the far right panels for each tissue.  Statistical significance was calculated using 
ordinary one-way ANOVA with multiple comparisons and the Brown–Forsythe and Welch 






4.2.2 Determine the therapeutic potential of CD8 T cells generated after intranasal 
delivery of α-GalCer and CpG-ODN, alone or in combination at both systemic and 
mucosal tissues (Aim 1.2) 
 Although infiltration of CD8 T cells to the tumor is generally considered indication 
of positive antitumor efficacy [123-125], functionality, in terms of killing capacity of the 
tumor infiltrating CD8 T cells is important for effective tumor eradication.  Therefore, I 
next examined the functionality of the antigen specific CD8 T in the spleen and FRT of 
vaccinated mice by using intracellular cytokine (ICC) staining for Granzyme B 
expression, a marker for cytotoxicity.   
Results from this analysis indicate that immunization with OVA plus the 
combination of α-GalCer and CpG-ODN produced significantly higher percentages of 
Granzyme B expressing antigen specific CD8 T cells (OT-1 cells), as well as the total 






Fig. 4.  Intranasal immunization employing the combination of α-GalCer and CpG-
ODN adjuvants significantly increases the frequencies of functional antigen-
presenting cells as well as overall CD8 T cells in the spleen and FRT.  Adoptively 
transferred OT-I cells were analyzed by flow cytometry in the spleen and FRT one week 
after immunization with OVA alone, or with the combination of α-GalCer and CpG-ODN.  
Average values for the frequencies of OT-I cells expressing GzmB (A), and overall 
frequency of CD8 T cells expressing GzmB (B) in the spleen and FRT of mice were 





These results demonstrate that intranasal immunization using the combination of 
α-GalCer and CpG-ODN adjuvants is an effective strategy to induce a robust and 
functional immune response in both systemic tissues, such as the spleen, and in the 
mucosal tissues, like FRT.   
Based on these results, I tested whether therapeutic HPV peptide vaccination 
employing the combination of α-GalCer and CpG-ODN adjuvants will induce anti-tumor 
efficacy against HPV genital tumors.   
 
4.3. (Aim 2) Determine whether intranasal delivery of HPV peptides together with 
the adjuvant combination will be effective in treating established HPV+ vaginal 
tumors. 
The therapeutic vaccine comprised of synthetic peptides corresponding to the E6 
and E7 oncoproteins of HPV-16, immunity which correlated with disease-free survival in 
women treated for CIN2/3 neoplasia[112].  Therefore, I tested the efficacy of vaccination 
using these peptides along with α-GalCer and/or CpG-ODN adjuvants for therapeutic 
efficacy in the orthotopic HPV vaginal tumor model. For simplicity sake the different 
vaccine compositions from here on out will be referred to as therapeutic vaccine 
containing α-GalCer (TVA), therapeutic vaccine containing CpG-ODN (TVC), and 
therapeutic vaccine containing α-GalCer and CpG-ODN (TVAC).      
Some of the results from this following section were also reported in a recently 
published manuscript (Sierra et. Al 2020)   
In the orthotopic HPV vaginal tumor model, mice were hormonally synchronized 




tumor induction, mice were imaged to ensure successful implantation of the tumor and 
sorted in order to ensure a similar average starting tumor size in the control group as 
well as in each of the treatment groups (TVA, TVC, or TVAC).  Therapeutic vaccines 
were administered intranasally on days 5 and 11 after tumor implantation.  Tumor size 
was monitored using the In Vivo Imaging System (IVIS) 200 in the institutional Small 
Animal Imaging Facility (SAIF) and reported as average radiance (p/s/cm2/sr) within a 
2x2cm circular region of interest (ROI) placed over the FRT on the imaging software 
Living Image.    
Tumor size was measured on a weekly basis and survival was charted up to 90 
days post-tumor implantation (Fig. 5A, 5B).  Mice treated with TVA or TVC exhibited 
tumor regression in a minor subset (20% and 33% respectively), but overall significantly 
better survival when compared to the untreated mice, or mice treated with the adjuvants 
alone.  On the other hand, the majority (85%) of mice treated with TVAC, showed 
complete tumor regression, and significantly higher survival rates in comparison to either 









Fig. 5. Intranasally administered TVAC is effective at treating established 
orthotopic HPV vaginal tumors.  Female C57BL/6J mice (n = 10 to 22) were 
hormonally synchronized and challenged with 2 × 104 TC-1-Luc cells into the vaginal 
cavity. Intranasal vaccinations using HPV peptide vaccine formulated with either α-
GalCer, CpG-ODN, or both α-GalCer and CpG-ODN (TVA, TVC, or TVAC, respectively) 
were administered on days 5 and 11 after tumor cell implantation; control groups included 
untreated mice, or mice immunized with the mixture of adjuvants without peptides 
(adjuvants alone). Survival analysis was recorded between each treatment group as well 
as the appropriate controls (A). Tumor size was measured using luciferase expression 
(ROI units) and plotted over time. The numbers of mice with complete tumor regression 
over total per group (minimum 10 mice per group) are shown in each panel for the 
different treatment groups (B). Significance in survival proportions was measured using 





4.3.1. Characterization of antitumor immune responses in mice treated with the 
different vaccines 
Because positive modulation of the tumor micro-environment, specifically 
enhanced levels of tumor infiltrating CD8 T cells have historically correlated with better 
treatment-mediated outcome in patients [126], I analyzed the tumor infiltrating leukocytes  
(TILs) in mice with vaginal orthotopic HPV tumors after the various treatments on day 18 
post-tumor implantation.  This time point was chosen based on the substantial 
differences in tumor size evident between treatment groups (Fig. 6A).   
The TILs were isolated as described in the methods section and analyzed by poly-
chromatic flow cytometry using 14 different antibodies to detect various cell surface and 
intracellular markers.  A typical gating strategy used for the flow cytometry analyses is 









Fig. 6.  Strategy for characterization of tumor infiltrating lymphocytes.  Tumor 
bearing mice were sacrificed one week after the second vaccination (V2) for 
characterization of tumor infiltrating leukocytes.  Tumor size significantly varies at this 
time point and thus was chosen to distinguish immunological differences between 
treatment groups (red oval) (A).  A generalized gating strategy is shown to depict 
characterization of the tumor infiltrating leukocytes (B). The first set of gates were set to 
detect cells based on size and granularity, followed by exclusion of dead cells and 
detection of CD45+ leukocytes.  Subsequently, the live CD45+ cells were differentiated 
as T cells based on the expression of CD3, followed by further characterization of 





We found that TVAC treated mice showed consistently higher frequencies of CD8 
T cells when compared to those treated with TVA and TVC, as well as the untreated 
control groups (Fig. 7A).  More importantly, significantly higher levels of antigen specific 
CD8 T cells were detected using the HPV16 E7 peptide tetramer in the TVAC treated 
mice, relative to other groups (Fig 7B).  Furthermore, granzyme B (GzmB) positive CD8 
T cells as well as E7-specific CD8 T cells, representative of cytotoxic functionality, were 
found at higher frequencies in TVAC treated mice, relative to those in all other groups 
(Fig. 5A, 5B, left panels, respectively).   
In addition to the CD8 T effector cells, I also investigated the frequencies of 
suppressor cell populations (MDSCs and Tregs) within the tumor.  Overall, a trend for 
higher density of CD8 T cells (measured in terms of cells/tumor weight) was observed in 
mice receiving TVAC when compared to TVA, TVC, or untreated controls, while the 
suppressor cells showed the opposite trend (Fig. 7C).  This translated into highest 
proportion of CD8 T cells relative to Tregs and MDSC combined in the TVAC treated 
animals, relative to those in other groups (60% CD8 in TVAC vs ~40% in TVA/TVC) as 









Fig. 7. Increased frequencies of effector CD8 T cells, relative to suppressor cells 
are correlates of protection by TVAC in mice with HPV genital tumors.  Highest 
percentages of total and cytotoxic (GzmB+) populations of CD8 T cells as well as HPV 
E7 antigen specific CD8 T cells were observed within the tumors of TVAC treated mice, 
relative to those treated with TVA and TVC or untreated controls (B).  Densities of CD8 
T cells and suppressor cells (Tregs and MDSCs) in the tumors of mice in the different 
groups were plotted numbers per tumor weight (C).  Individual frequencies of tumor 
infiltrating CD8 T cells, Tregs, and MDSCs among the three populations together reveal 
the dominance of CD8 T cells over the two suppressor together in the tumors of TVAC 
treated mice, relative to other groups (D).  Statistical significance was calculated using a 





4.3.2. Comparative analyses of immune correlates for antitumor efficacy between 
TVAC and the combination of TVA and anti-4-1BB immunotherapy  
In comparing the antitumor efficacy of TVAC with TVA plus anti-4-1BB treatment 
(TVA + ɑ4-1BB) against established vaginal TC-1 tumors [114], there was no observed 
significant difference between these two treatments in terms of tumor regression and 
tumor-free survival (Fig. 8A).  Therefore, I next investigated, by flow cytometry, the tumor 
infiltrating lymphocytes isolated from mice treated with TVA + ɑ4-1BB and TVAC one 
week after the second vaccination.  Although comparable levels of total and HPV E7 
antigen specific CD8 T cells were induced in both treatment groups (Fig. 8B), we did not 
detect the highly cytotoxic CD4 and CD8 T cell subsets called ThEO, and TcEO cells, 
respectively, in TVAC treated mice, which were the defining feature of the efficacy of the 
TVA + ɑ4-1BB treatment (Fig. 8C, 8D).  We observed a trend for higher frequencies of 
total and antigen-specific CD8 T cells expressing Granzyme B or IFN-γ in TVAC treated 
mice, but the differences did not reach significance (Fig. 8E).  Mice treated with TVA + 
ɑ4-1BB, however, did show significantly higher levels of liver enzymes in  the blood-
Aspartate transaminase (AST) and alanine aminotransferase (ALT)- which serve as 
indicators of systemic toxicities attributed to immune checkpoint therapy, relative to those 








Fig. 8. Comparable antitumor efficacy for TVAC and TVA + ɑ4-1BB treatments.  
Female C57BL/6J mice with vaginal TC-1 tumors were treated with TVAC or TVA + ɑ4-
1BB as described in the methods and monitored for survival (A).  TIL analysis was carried 
out to compare CD8 T cell frequencies as well as antigen specific CD8 T cells (B).  TcEO 
cells (classified as EOMES+ KLRG-1+ CD8 cells were found to be a unique feature of 
TVA + a4-1BB treatment (C, D).  Functionality of overall CD8 T cells (E, G) and HPV E7 
antigen specific CD8 T cells (F) were also compared between these two treatments.  
Liver enzyme levels were recorded in blood three days after each vaccination and 
reported as units of aspartate transaminase (AST) or alanine aminotransferase (ALT) 
per liter (L).  Significance in survival proportions was measured using the log-rank test; 
ns=not significant.  Statistical significance between different treatment groups was 
calculated using a One-Way ANOVA with multiple comparisons. p<0.00005 (****), 






4.3.3. Investigate the contribution of CD8 T cells for the anti-tumor efficacy of TVAC 
treatment 
Since the data in Fig. 7 showed induction of CD8+ T cells as an important correlate 
for the efficacy of TVAC, I tested weather and to what extent depletion of CD8 T cells 
would abrogate the protection.  Vaginal TC-1 tumor-bearing mice treated with TVAC 
were administered an isotype control or anti-CD8 depletion antibody every three days 
starting one day prior to tumor induction, and untreated mice served as an additional 
control (Fig. 9A). Blood collected over time was analyzed to confirm depletion of CD8 T 
cells, Day 17 post tumor induction flow plots are depicted as representative graphs (Fig. 
9B).  I observed near complete depletion of CD8 T cells (99.6% decrease relative to 
control) in mice receiving the CD8 depletion antibody, which correlated to significant 
abrogation of the anti-tumor efficacy of TVAC in terms of significantly lower survival due 
to tumor growth when compared to the isotype control (Fig. 9C, 9D).   
These results indicate that the CD8 T cell response generated by the intranasal 










Fig. 9. CD8 T cells are essential for TVAC efficacy against vaginal TC-1 tumors in 
mice.  Tumor bearing mice were vaccinated intranasally as previously described with 
TVAC on days 5 and 11, and either treated with a CD8 depletion antibody or IgG control 
once every three days.  An untreated group served as an additional control (A).  CD8 
depletion was monitored in the blood over the course of multiple time points using FACS.  
Representative FACS plots gated on live CD3 population show complete CD8 depletion 
only in mice receiving depletion antibody at one week post-tumor implantation (B).  
Tumor growth and survival were monitored in mice and plotted over time (C). 






4.3.4-Role of NK and NKT cell subsets in TVAC efficacy 
The composition of TVAC includes the adjuvant α-GalCer known to promote 
antigen presentation via the activation of NKT cells, which are important for innate 
immune surveillance via direct cytotoxic functions. Therefore, I investigated their role in 
the observed efficacy of TVAC against the vaginal TC-1 tumor model.  
NKT cells are classified into at least two main subsets, type 1 NKT cells and Type 
2 NKT cells.  Type 1 NKT cells, which are more commonly referred to as invariant NKT 
(iNKT), express the invariant Vα14-Jα18 in mice and Vα24-Jα18 in humans, and are 
generally identified in flow cytometry as CD3 intermediate and NK1.1+[130].  They are 
strongly reactive to α-GalCer and can be identified using α-GalCer loaded CD1d tetramer 
reagents.   
Type 2 NKT cells, however, are described as the more evasive population of NKT 
cells due to the fact that they do not express a semi-invariant TCR chain like the iNKT 
cells and can’t be identified with α-GalCer loaded CD1d tetramer [131], instead they have 
diverse TCRs but are still CD3+, NK1.1+.  Under normal conditions, these cells harness 
anti-inflammatory capabilities, however, recent studies have indicated that CpG-ODN 
can shift the capabilities of type 2 NKT cells to an inflammatory response with anti-tumor 
capabilities [132].  Based on this information, I hypothesized that TVAC comprising both 
α-GalCer and CpG-ODN adjuvants may be engaging type 2 NKT cells for their potential 
contribution towards the observed anti-tumor efficacy.   
Interestingly, one of the primary reasons early clinical trials using α-GalCer 




comparison to mouse models[108].  Given that type 2 NKT cells are more prominent than 
iNKT in humans [133], engagement of these cells could potentially lead to better clinical 
outcomes.   By gating on CD3+NK1.1+ cells in the flow cytometry analyses, I attempted 
to identify these cell within the TC-1 tumors of untreated mice and those administered 
the different vaccine formulations (Fig 10A).   
Tumor bearing mice were treated with TVA, TVC, or TVAC and sacrificed three 
days after the second dose.  This time point was chosen due to the rapid response of 
NKT cells after intranasal stimulation where the peak response is typically at three days 
[107].  I observed slight increase in the levels of iNKT cells (Type 1 NKT cells) in the 
tumors of TVAC and TVA treated mice, (Fig 10B) with TVAC treated mice exhibiting the 
highest number of IFN-γ expressing iNKT cells among the different groups of mice(Fig. 
10C).  The frequency of type 2 NKT cells increased within the tumor in TVC treated 
groups, however, no differences in the numbers of IFN-γ positive cells was recorded in 






Fig. 10. Detection and characterization of NKT cell subsets in the vaginal TC-1 
tumors of vaccinated mice.  Tumor bearing mice were treated on days 5 and 11 as 
previously described with either TVA, TVC, or TVAC.  Three days after the second 
vaccination, lymphocytes were collected and analyzed according to the gating strategy 
shown (A).  The CD1d tetramer positive cells were classified as type I NKT (iNKT) cells, 
while CD1d tetramer negative were classified as type 2 NKT cells.  Frequencies of each 




In order to evaluate the potential contributions of NK and NKT cells subsets for 
the anti-tumor efficacy of TVAC, I conducted a NK depletion study. Because there is no 
single antibody to deplete specifically the NKT cells, I used the PK136 antibody that 
depletes both NK and NKT cells subsets. The tumor bearing mice were treated with 
TVAC as previously described, on days 5 and 11, along with IP administration of the 
PK136 antibody or a control IgG one day prior to each TVAC treatment (days 4 and 10 
post-tumor implantation) and weekly thereafter.  Blood was collected weekly and 
analyzed to ensure NK depletion.  Representative flow plots depict specific NK depletion 
in the blood and are plotted as averages per antibody treatment (Fig. 11A, 11B).  Survival 
and average tumor growth were monitored over time (Fig. 11C, 11D), and individual 
mouse tumor growth is also shown (Fig. 11E) 
Despite near complete depletion of NK cells subsets, I observed only marginal 
decrease in TVAC-mediated protection, in terms of tumor growth and survival 
percentage. These results suggest minor contribution by the NK and NKT cells subsets 
towards the observed antitumor efficacy of TVAC against vaginal TC-1 tumors, the 









Fig. 11. Depletion of NK cells does not significantly influence the efficacy of TVAC 
against orthotopic vaginal TC-1 tumors.  Vaginal tumor bearing mice were 
administered either PK136 antibody or control IgG via the IP route, one day prior to each 
vaccination, and weekly thereafter.  TVAC was administered intranasally as previously 
described on days 5 and 11.  Blood was analyzed weekly to ensure proper NK depletion, 
and representative flow plots as well as numeric summaries are shown (A, B).  Mice were 
monitored for survival (C) and imaged weekly to monitor tumor growth (D, E).  Statistical 





4.4. (Aim 3) Investigate the effect of tumor location and route of vaccine 
administration on the therapeutic efficacy of TVAC   
Based on the potent antitumor efficacy observed for TVAC administered by the 
intranasal route against established HPV orthotopic tumor model of vaginal /TC-1 
tumors, I tested whether the vaccine is equally efficacious against subcutaneously 
implanted flank tumors (aim 3.1),  and whether the vaccine will be effective if delivered 
by systemic subcutaneous route (aim 3.2).   
4.4.1 Determine the efficacy of intranasally administered TVAC against subcutaneous 
HPV tumors.   
Up to 23% of Stage IV HPV genital cancers are reported to spread into other parts 
of the body [134], therefore I set out to determine whether intranasally administered 
TVAC would also be effective in treating tumors at non-mucosal location by injecting the 
TC-1 tumor cells subcutaneously on the flank.   
Naïve female C57Bl6/J mice were implanted with 200,000 TC-1 Luc cells 
subcutaneously in the flank, and immunized on days 5 and 11 as described in the 
methods.  Mice were administered either TVA, TVC, or TVAC by the intranasal route and 
monitored for tumor growth and survival (Fig. 12A).  Tumor size was measured three 
times per week using calipers and plotted as area (mm2) over time.   
I observed nearly 30% of the TVAC treated mice with subcutaneous flank tumors 
exhibit tumor regression and improved survival relative to any other treatment (Fig. 12B). 
This level of antitumor efficacy for the intranasal TVAC treatment is lower than the 70% 





Fig. 12. Intranasal delivery of TVAC shows limited efficacy in subcutaneously 
implanted TC-1 tumors.  Groups of 57BL/6 female mice were injected with 2x106 TC-
1Luc cells subcutaneously on the flank and treated by the intranasal route with either 
TVA, TVC, or TVAC on days 5 and 11 after tumor induction (A), a separate group of 
untreated mice served as control group. Survival rates (B), and tumor growth were 




In order to determine the immune correlates for the observed partial protection of 
TVAC against the subcutaneous tumors, tumor infiltrating lymphocytes were collected 
for flow cytometry analysis one week after the last treatment.   
The frequencies of overall and antigen specific CD8 T cells were significantly 
increased in the tumors of mice treated with TVAC when compared to untreated control 
mice, similar to the data from the analyses of TILs from mice with vaginal tumors (Fig. 
13A, 13B).  Furthermore, granzyme B expressing total and antigen specific CD8 T cells 
were also at higher frequencies in mice receiving TVAC, relative to that in the untreated 
mice (Fig.13C, 13D).  This data indicates that intranasal administration of TVAC is 
effective at inducing a robust immune response in flank tumors, but was insufficient to 
afford the level of tumor regression matching that in the vaginal tumor model (Fig. 7).  
Therefore, I investigated for changes in the frequencies of immune suppressive Tregs 
and MDSCs and compared the effector to suppressor cell ratios in the different groups 
of mice treated for subcutaneous flank tumors.  Although the CD8 T cells in the flank 
tumors were found at higher percentages in the TVAC treated mice when compared to 
the untreated and TVC treated mice, the density of CD8 T cells in the flank tumors were 
similar in TVA and TVAC treated mice (Fig. 13E).  Treg and MDSC populations were 
also similar in TVA and TVAC groups, with lower levels found in the untreated and TVC 
treated groups (Fig. 13F, 13G).  Unlike the trend we saw in the TVAC administered mice 
with vaginal tumors, a stronger CD8 T cell response was not observed when compared 
to the suppressor cell populations, resulting in no improvement of the ratio of effector 





Fig. 13. Tumor infiltrating lymphocytes in the flank tumors of mice treated with 
TVAC by the intranasal route.  Groups of 57BL/6 female mice were injected with 2x106 
TC-1Luc cells subcutaneously on the flank and treated by the intranasal route with either 
TVA, TVC, or TVAC on days 5 and 11 after tumor induction (A), and a separate group of 
untreated mice served as control group. Single cell suspensions from flank tumors 
collected one week after completion of the last immunization were analyzed by flow 
cytometry.  Frequencies of total and antigen specific CD8 T cells (A and B) as well as 
respective functional subsets (C and D) were enumerated in different groups of mice.  
Densities of CD8, Treg, and MDSCs populations in terms of numbers of cells/tumor 
weight were plotted (E).  The ratios of CD8 to cells to each of the suppressor cell subsets 
as well as total suppressor cells were shown (F).  Statistical significance was calculated 




Early diagnosis and treatment of tumors offers higher rates of survival [135, 136]. 
It is therefore possible that delayed treatment would most likely results in the 
accumulation of higher numbers of immune suppressive cells, including MDSCs and T 
regulatory cells in the tumor microenvironment.  Because the experimental protocol for 
subcutaneously implanted flank tumors involved injection of a higher dose of tumor cells 
(200,000), relative to that for the vaginal tumors (20,000), I hypothesized bigger flank 
tumor size prior to the start of the treatment/vaccination regimen (day 5) allowing for 
greater accumulation of immune suppressive cells resulting in the observed lower 
efficacy of the therapeutic vaccine, TVAC, relative to that in the vaginal tumor model 
studies.   
To test this hypothesis, specifically MDSC accumulation as a major reason for the 
reduced efficacy of TVAC against flank TC-1 tumors, I utilized anti-Gr-1 antibody to 
deplete MDSCs. The antibody was administered by the intraperitoneal route weekly, 
starting two days after tumor implantation to mice treated with TVAC and control 
untreated mice (Fig. 14A).  Blood was analyzed by flow cytometry at several time points 
to ensure depletion of MDSCs (Fig 14B, 14C). Tumor growth and survival were recorded 
over time (Fig. 14D, 14E, 14F).   
I observed that depletion of the MDSCs did not provide any significant advantage 
in survival or reduction of tumor size/growth rate in either the TVAC treated or control 
groups of mice.  This indicates that MDSC accumulation prior to treatment may not be 
contributing to the diminished TVAC efficacy in the flank implanted TC-1 tumors. 




through soluble factors could be at overwhelmingly higher frequencies/densities in the 










Fig. 14. MDSCs depletion fails to increase efficacy of TVAC in subcutaneously 
implanted flank TC-1 tumors.  Tumor bearing mice were treated with anti-GR-1 
antibody (IP) weekly, starting two days after tumor implantation followed by TVAC (IN) 
on days 5 and 11 as previously describe in the methods section (A).  Proper MDSC 
depletion was ensured via flow cytometry at several time points throughout treatment; 
representative gating strategies are shown for the detection of MDSCs in the blood and 
are shown for each treatment group (B, C). Tumor growth was monitored over time (D, 
E), and survival was recorded (F).  Significance in survival proportions was measured 





Thus, the timing of vaccine administration with respect to tumor burden could 
potentially be a confounding factor for the weaker immune protection by the TVAC.  In 
fact, a comparison of tumor size determined by the luciferase expression based imaging 
analyses, revealed a significantly larger starting size for the subcutaneous flank tumors 
relative to the vaginal tumors correlating with the relative differences observed for the 
vaccine-mediated efficacy (Fig. 15B).  Because subcutaneously implanted tumors with 
less number of cells in the inoculum tend to spontaneously regress in immune competent 
mice, reducing the number of tumor cells for initiating the tumor growth was not an option.  
Therefore, I tested initiating vaccine treatment on day 1 after subcutaneous injection of 
tumor cells, followed by the second dose delivered on day 5, thus keeping the intervals 
between the two vaccinations the same as in the previous experiment (Fig. 15 A).  
Importantly, the size of the subcutaneously growing flank tumors at day 1 was 
comparable (based on luciferase expression) to that of vaginal tumors at day 5 (when 
the immunization was initiated) (Fig. 15B).  In this vaccination regimen, TVAC-treated 
mice exhibited effective control of tumor growth in about 75% of mice with significant 
survival and these outcomes are comparable to that seen for vaginal tumors treated with 
this vaccine TVAC (Fig. 15 C, 15D).  Furthermore, TIL analysis revealed that treatment 
of the smaller subcutaneously flank tumors treated on day 1 resulted in significantly 
higher concentrations of CD8 T cells (per gram of tumor), when compared to that in the 









Fig. 15. Flank and vaginal tumors matched for pre-treatment size are responsive 
to intranasally delivered TVAC.  Groups of C57BL/6 female mice were injected with 
2x106 TC-1Luc cells subcutaneously on the flank and treated by the intranasal route with 
either TVA, TVC, or TVAC on days 1 and 6 post-tumor induction (A).  Vaginal tumor size 
on day 5 compared to that of flank tumors on days 1 versus day 5 (B).  Tumor bearing 
mice were followed for survival and tumor growth (C, D).  Density of CD8 T cells in the 
tumor one week after second dose of TVAC are compared between mice with smaller 
flank tumors receiving TVAC treatment on day 1 (small SC TVAC) versus the in mice 
with larger flank tumors that began treatment on day 5 (Large SC TVAC) (E).  Statistical 
significance was calculated using One-Way ANOVA test with multiple comparisons.  




4.4.2. Determine the importance of mucosal intranasal route of immunization for the 
efficacy of TVAC against vaginal TC-1 tumors (Aim 2.2) 
The mucosal immune system is a compartmentalized portion of the overall 
immune system.  Because HPV is primarily transmitted via mucosal surfaces, a major 
rationale for adapting mucosal intranasal route of immunization is to not only induce 
robust antigen specific CD8 T cell response, but also to promote their trafficking to the 
female reproductive tract for efficient tumor clearance.  While data obtained from 
intranasal delivery of TVAC demonstrated strong efficacy against vaginal HPV tumors, it 
is not clear whether systemic route of vaccine administration would be inferior or equally 
effective at protecting against vaginal HPV tumors.  
To begin testing this, the OT-I transgenic mouse model was adapted to first 
monitor distribution of antigen specific CD8 T cells across multiple systemic and mucosal 
tissues after systemic intramuscular immunization regimen.  A total of 1x106 OT-I cells 
were adoptively transferred into congenic C57Bl/6 mice followed one day later by 
treatment with OVA plus the combination of α-GalCer and CpG-ODN adjuvants either by 
the mucosal intranasal or systemic intramuscular route.  Frequencies of OT-I cells were 
determined at various tissues one week later.   
While a significantly higher frequency of OT-I cells was observed in the spleens 
of mice receiving the systemic, relative to the mucosal route of immunization (Fig. 16A), 
there was no significant difference in the proportions of these antigen specific CD8 T 
cells within the FRT (Fig. 16B).  Furthermore, the cytotoxic functionality, in terms of 




different between mice receiving the systemic versus intranasal immunization (Fig. 16C), 
suggesting that both routes of vaccination are equally efficient in inducing functional 






Fig. 16. Mucosal and systemic routes of immunization induce similar antigen 
specific immune response at FRT.  Mice were adoptively transferred with 1x106 OT-I 
cells one day prior to being treated with either intranasal or systemic administration of 
OVA or OVA + α-GalCer + CpG-ODN.  Percentages of OT-I cells were examined in the 
spleen and FRT of treated mice (A, B).  Granzyme B expressing CD8 T cells were 
examined within the FRT (C).  Statistical significance was calculated using the one-way 





Based on the data showing the potency of systemic immunization to induce 
antigen-specific cytotoxic CD8 T cell responses in the FRT, I also compared mucosal 
and systemic routes of TVAC delivery to treat vaginal HPV tumors  Since it is known that 
multiple doses of α-GalCer delivered via systemic route of immunization induce NKT cell 
anergy, and thereby impede development of adaptive immunity to co-administered 
antigens [107], for subcutaneous immunization mice were dosed only once with TVAC 
(containing the α-GalCer along with CpG-ODN) on day 5.    
Delivery of TVAC by either SC or IN route was equally effective at treating the 
HPV vaginal tumors as observed in terms of tumor growth and survival (Fig. 17A).  
Analysis of TILs suggested that intranasal immunization was more efficient at inducing 
CD8 antigen specific T cells in the tumor, when compared to SC immunization (Fig. 17C, 
17D).  Despite this difference, overall efficacy in terms of survival advantage was not 
statistically different in mice receiving the TVAC by the two different routes.   
This data indicates that the therapeutic HPV peptide vaccine containing α-GalCer 
and CpG adjuvants (TVAC) is equally effective when delivered in two doses by the 
intranasal route or in one dose by the subcutaneous route at eliciting anti-tumor immunity 









Fig. 17. Single dose of SC TVAC is effective at treating vaginal tumors.  Vaginal 
tumor bearing mice were immunized on days 5 and 11, intranasally, as previously 
described, or only on day 5 via the subcutaneous route and monitored for tumor growth 
and survival (A, B).  Tumor infiltrating lymphocytes were analyzed on day 18 post-tumor 
implantation and are reported as frequency of parent population (C, D).  Statistical 
significance was calculated using one-way ANOVA with multiple comparisons. p<0.005 





CHAPTER 5: DISCUSSION AND FUTURE DIRECTIONS  
Data from this dissertation demonstrates the antitumor efficacy of mucosal 
intranasal vaccination regimen comprised of peptides corresponding to immunogenic 
sequences in the HPV-16 oncoproteins E6 and E7 and the combination of α-GalCer and 
CpG-ODN adjuvants (TVAC) in an established preclinical HPV genital tumor mouse 
model.  This is particularly significant because sustained tumor regression-free survival 
was achieved solely by vaccine-induced cytotoxic effector immunity successfully 
overcoming the immunosuppressive tumor microenvironment. Importantly, the 
therapeutic vaccine formulation was effective without the need to employ immune 
checkpoint therapy that often suffers from systemic toxicities [128, 137]. Despite many 
efforts to overcome the toxicities [138, 139], treatment related costs, widespread 
availability/accessibility, and ease of administering ICT to patients in resource-limited 
areas of the world are the major hurdles. In this regard, the needle-free intranasal 
vaccination regimen employing clinically relevant adjuvants to promote immunogenicity 
demonstrated to be efficacious in this investigation may be an ideal choice for the 
treatment of HPV+ cervical cancer.  Our data demonstrates that in the absence of ICT, 
intranasally delivered TVAC exerted significant induction of antigen-specific CD8 T cells 
resulting in substantial increase in the ratios of effector CD8 T cells to the 
immunosuppressive Tregs and MDSCs within the TME.   
Additionally, serum levels of liver enzymes AST and ALT that serve as surrogates 
for toxicity measurements were comparable between mice with vaginal HPV tumors in 




containing the combination of α-GalCer and CpG-ODN adjuvants.  However, these 
measurements of liver toxicity in mice receiving the α4–1BB ICT were significantly above 
the normal range (Fig. 7).  
We reported earlier that the significant antitumor efficacy afforded by the 
therapeutic HPV peptide vaccination employing α-GalCer adjuvant and supplemented 
α4-1BB ICT was the induction of a unique subset of Eomesodermin expressing CD4 and 
CD8 T cells with high cytotoxic potential (ThEO and TcEO cells, respectively) owing to 
their capacity for producing multiple granzymes [140].  Even though TVAC treated mice 
did not exhibit induction of this novel T cells subsets, the frequencies of total and antigen-
specific CD8 T cells as well as the antitumor efficacy in terms of tumor regression-free 
survival were comparable. It is possible that the therapeutic efficacy of TVAC may be 
also due to the engagement of other cytotoxic effector mechanism including the 
contributions from NK cells and/or NKT cells, a possibility that needs to be evaluated in 
future studies.  Since the tumor killing functions of the CD8 T cells were not directly 
assessed in either of the treatments (α4-1BB supplemented single-adjuvant vaccine and 
TVAC), it is difficult to surmise whether enhanced cytotoxic potential of CD8 T cells was 
an important feature of efficacy in the TC-1 vaginal tumor model.  
The unique therapeutic potential of TVAC is likely due to the ability of the adjuvant 
combination, relative to each adjuvant alone, in the vaccine to impart dual licensing of 
dendritic cells and promoting induction of stronger CD8 T cell responses.  While CpG-
ODN is known to induce dendritic cell (DC) activation through Toll-Like Receptor (TLR) 




strong maturation of DCs, a phenomenon referred to as alternative licensing [26, 141]. It 
is suggested that DC receiving the signals from dual licensing can induce strong 
recruitment and activation of naïve CD8 T cells through the actions of two independent 
sets of chemokines [122, 142, 143]. It is therefore possible that the combination of α-
GalCer and CpG-ODN adjuvants, relative to each adjuvant alone, and intranasal delivery 
enabled promotion of strong antigen-presentation in mucosal DCs, resulting in the 
induction and recruitment of high levels of antigen-specific CD8 T cells to the tumor.  
While studies in this investigation were limited by less efficient isolation of adequate 
numbers of mucosal dendritic cells from the nasal associated lymphoid tissues, it is 
known that higher DC activation is directly correlated with enhanced antigen presentation 
and thus CD8 response.  Within the tumors of mice treated with TVAC, higher 
frequencies of overall CD8 T cell as well as functional subsets of HPV-specific CD8 T 
cells expressing granzyme B were observed, and the number of CD8 T cells exceeded 
those of the immunosuppressive Tregs and MDSCs together. This data showing 
significant induction of functional CD8 T cells in mice treated with TVAC is in line with 
reports in the literature for their role in antitumor efficacy, and proved to be the primary 
driver of protective immunity in the vaginal TC-1 model, as CD8 depletion completely 
abrogated vaccine efficacy (Fig. 4) [144]. Compatibility of different TLR agonists with α-
GalCer for enhanced DC-mediated activation of CD8 T cells has been described in vitro 
using co-cultures of DC and T cells and after subcutaneous delivery in vivo [109, 110, 
122, 145-147]. However, my results show for the first time the effectiveness of α-GalCer 




of functional antigen-specific CD8 T cell responses in systemic and mucosal tissues, and 
more importantly for curative efficacy against HPV genital tumors.  These results are in 
line with previous data from our group that showed intranasal delivery of vaccines is an 
effective strategy to drive significant levels of antigen-specific CD8 T cell responses at 
the genital mucosa [117].  
Intranasally delivered TVAC was also effective at treating subcutaneously 
implanted tumors in the flank supporting its wider utility in cases where the cancer has 
spread out of the genital mucosal tissues.  Albeit, the efficacy of TVAC was significantly 
reduced against larger size tumors, despite the induction of strong CD8 T cell response, 
implicating that the larger flank tumors may have significantly accumulated suppressor 
cells, as commonly seen in patients [19].  Interestingly, however, depletion of MDSCs 
alone was not enough to overcome immune suppression and restore antitumor efficacy 
of TVAC (Fig. 14).  These results suggest contribution of additional immune suppressive 
populations like Tregs in the tumor microenvironment and a combined depletion of both 
MDSCs and Tregs at the start of tumor induction could improve antitumor efficacy of the 
vaccination regimen. It is therefore, important and informative to determine whether the 
frequency and/or density of functional populations of total and antigen specific CD8 T 
cells within the tumor are sufficient for inducing tumor regression.  In this aspect, recent 
investigations of MDSCs have identified subsets with  differing immunosuppressive 
potentials, therefore, inclusion of additional markers for characterization of these subsets 
and determining functionality of tumor-infiltrating MDSCs would be beneficial to further  




studies [148].  Because surface markers and gating strategies alone cannot discriminate 
some MDSC subsets from monocytes and neutrophils, one method of identifying MDSC 
functionality is the inclusion of a marker to detect Arginase  [149].  Arginase is an enzyme 
produced by immunosuppressive MDSCs which depletes L-Arginine, inhibiting T-cell 
function [150].  In addition, in-vitro studies co-culturing purified suppressor MDSCs with 
increasing number of effector cells is an alternate option for further investigating the 
effector to suppressor cell ratios within the TME.  Additionally, analysis for the expression 
of immune checkpoint inhibitory receptors/ligands (such as PDL-1/PD-1) within the tumor 
microenvironment as well as comparison of the ratios of CD8: MDSC + Treg cells in 
relation to tumor size would be instrumental to further refine the intranasal vaccination 
strategy described in this investigation.   
Another important aspect of the intranasal route of TVAC delivery that included 
delivering multiple doses of the vaccine formulation containing the α-GalCer and CpG-
ODN adjuvants  to inducing immunity at the FRT is the ability to circumvent NKT cell 
anergy, which results from multiple doses of α-GalCer if delivered by systemic 
immunization [151, 152].  Even though this investigation did not specifically determine 
repeated activation of iNKT cells after each vaccination, previous reports from our lab 
have showed the increase of antigen specific T cell immunity resulting from multiple 
mucosal doses of α-GalCer as a result of repeated NKT cell stimulation [105, 107].  It 
would be useful to also investigate the effect of administering multiple doses of α-GalCer 
and CpG-ODN by the intranasal route on different NKT cell subsets.  In this regard it is 




humans and may be an essential cell population for overcoming immune suppression in 
tumors [132, 133].  Interestingly, recent literature reports suggest that targeting these 
type 2 NKT population through the use of CpG-ODN can shift their immune suppression 
phenotype to an inflammatory anti-tumor response [153, 154].   
Although NK depletion studies using the anti-PK136 antibody did not significantly 
decrease the efficacy of TVAC in the vaginal tumor model (Fig. 10), we cannot conclude 
that NK1.1 expressing cells (including NKT cells) are unnecessary for TVAC efficacy.  In 
fact, if NKT cells, in particular, did not contribute to TVAC efficacy, we would expect TVC 
to induce similar anti-tumor results as TVAC since α-GalCer specifically induces anti-
tumor immunity through NKT cell engagement and activation.  One explanation as to 
why NK1.1 depletion antibody resulted in minimally reduced TVAC efficacy is due to the 
NK1.1 negative NKT cell subsets.  Studies show that circulating and thymic immature 
NKT cells do not express NK1.1, and NKT cells activated in vitro, also downregulate 
NK1.1 [155].  Therefore, it is possible that immature NKT cells contributed to the TVAC 
efficacy in mice treated with PK136 antibody.   
Several groups are currently developing models to further study NK and NKT cells 
separately, and understandably it is a difficult task due to the many shared phenotypic 
markers and functions.  One group described the development of an NKT specific 
monoclonal antibody that could be utilized in future studies for further investigation of 
NKT cells vs NK cells in TVAC efficacy [156].   
While the majority of results from this investigation established the advantages for 




intranasal route, one dose of TVAC delivered via the subcutaneous systemic (SC) route 
also exhibited anti-tumor efficacy against genital HPV tumors (Fig. 17).  However, one 
caveat to concluding equal potency of systemic vaccination to induce protection against 
the vaginal mucosal tumors is that the SC vaccination was administered close to the hind 
limbs, and therefore, it is likely that a combination of the lymphatic drainage pattern and 
nearby inflammatory tumor environment aided in directing the antigen-specific immune 
responses to the FRT [157].  It is therefore, important to test the efficacy of TVAC 
delivered at a different SC location such as the back of the neck and analyzing the 
draining lymph nodes as well as vaginal tumor infiltrating lymphocytes.   
Overall, results from this investigation demonstrated the efficacy TVAC against 
established vaginal tumors and smaller size flank tumors via induction of strong total and 
antigen-specific cytotoxic effector CD8 T cells.  Both the vaccine and the immunization 
regimen were however less optimal for treating much advanced bigger size tumors where 
additional strategies to overcome immune suppression may have to be explored. Given 
this, it is tempting to speculate that mucosal intranasal delivery of TVAC could be an 
option to treat pre-cancerous cervical intraepithelial lesions (CIN) that are detected 
during a pap smear testing procedure. However, standard practice after a CIN (stage I) 
diagnosis is to wait and determine whether the infection and pre-cancerous growth 
resolves itself within a few months.  If the growth is not naturally resolved, it progresses 
to CIN II/III stages and those patients undergo surgery for the removal of the affected 
area, which pose quality of life concerns.  In this setting it could be advantageous to 




an early treatment option.  Unfortunately, there are no currently available preclinical 
models for pre-cancerous lesions. In this regard, a recent study described the potential 
of a new, infection-based HPV tumor model for HPV head and neck squamous cell 
carcinomas which could be promising for use as a vaginal tumor model as well [158].  
HPV infections naturally take several years to develop, thereby allowing the tumor 
microenvironment to initiate immune-suppression mechanisms, otherwise not 
established in orthotopic models such as the one utilized here.  Additionally, some critics 
argue that inflammation is induced during the tumor implantation process, aiding 
whatever therapeutic treatment administered, however, an infection-based model such 
as the one described above could circumvent these concerns.  In future studies, 
intranasal administration of TVAC in primates would be necessary to ensure proper and 
robust Th1 immunity at the FRT prior to promoting this therapeutic approach in clinics.  
It would also be interesting to compare with the therapeutic HPV synthetic long peptide 
(SLP) vaccine, which has shown some level of efficacy against high-grade vulvar lesions 
but was ineffective against invasive cervical cancer in clinical trials[159-161].   
CHAPTER 6: REFERENCES 
1. Gupta, R.K. and G.R. Siber, Adjuvants for human vaccines—current status, problems 
and future prospects. Vaccine, 1995. 13(14): p. 1263-1276. 
2. Garbuglia, A.R., D. Lapa, C. Sias, M.R. Capobianchi, and P. Del Porto, The Use of Both 
Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease. 
Frontiers in immunology, 2020. 11: p. 188-188. 
3. Vaccine Ingredients. Vaccubes [website] 2020  [cited 2021 03/11/2021]; Available from: 
https://www.vaccines.gov/basics/vaccine_ingredients. 
4. Knudson, A.G., Jr., Mutation and cancer: statistical study of retinoblastoma. Proc Natl 
Acad Sci U S A, 1971. 68(4): p. 820-3. 
5. Hanahan, D. and Robert A. Weinberg, Hallmarks of Cancer: The Next Generation. Cell, 




6. Bevan, R.J. and P.T.C. Harrison, Threshold and non-threshold chemical carcinogens: A 
survey of the present regulatory landscape. Regulatory Toxicology and Pharmacology, 
2017. 88: p. 291-302. 
7. Blackadar, C.B., Historical review of the causes of cancer. World journal of clinical 
oncology, 2016. 7(1): p. 54-86. 
8. Liao, J.B., Viruses and human cancer. The Yale journal of biology and medicine, 2006. 
79(3-4): p. 115-122. 
9. White, M.K., J.S. Pagano, and K. Khalili, Viruses and Human Cancers: a Long Road of 
Discovery of Molecular Paradigms. Clinical Microbiology Reviews, 2014. 27(3): p. 463. 
10. Laga, M., J.P. Icenogle, R. Marsella, A.T. Manoka, N. Nzila, R.W. Ryder, S.H. Vermund, 
W.L. Heyward, A. Nelson, and W.C. Reeves, Genital papillomavirus infection and cervical 
dysplasia--opportunistic complications of HIV infection. Int J Cancer, 1992. 50(1): p. 45-
8. 
11. Klencke, B.J. and J.M. Palefsky, Anal cancer: an HIV-associated cancer. Hematol Oncol 
Clin North Am, 2003. 17(3): p. 859-72. 
12. Labarga, P., Cancer in HIV patients. AIDS Rev, 2013. 15(4): p. 237-8. 
13. Schiller, J.T. and D.R. Lowy, Vaccines to prevent infections by oncoviruses. Annual 
review of microbiology, 2010. 64: p. 23-41. 
14. Bansal, A., M.P. Singh, and B. Rai, Human papillomavirus-associated cancers: A growing 
global problem. International journal of applied & basic medical research, 2016. 6(2): p. 
84-89. 
15. de Villiers, E.M., C. Fauquet, T.R. Broker, H.U. Bernard, and H. zur Hausen, Classification 
of papillomaviruses. Virology, 2004. 324(1): p. 17-27. 
16. Van Doorslaer, K., Q. Tan, S. Xirasagar, S. Bandaru, V. Gopalan, Y. Mohamoud, Y. 
Huyen, and A.A. McBride, The Papillomavirus Episteme: a central resource for 
papillomavirus sequence data and analysis. Nucleic Acids Res, 2013. 41(Database 
issue): p. D571-8. 
17. Graham, S.V., Human papillomavirus: gene expression, regulation and prospects for 
novel diagnostic methods and antiviral therapies. Future microbiology, 2010. 5(10): p. 
1493-1506. 
18. Graham, Sheila V., The human papillomavirus replication cycle, and its links to cancer 
progression: a comprehensive review. Clinical Science, 2017. 131(17): p. 2201-2221. 
19. Zhou, C., Z.K. Tuong, and I.H. Frazer, Papillomavirus Immune Evasion Strategies Target 
the Infected Cell and the Local Immune System. Frontiers in oncology, 2019. 9: p. 682-
682. 
20. Stanley, M., Pathology and epidemiology of HPV infection in females. Gynecol Oncol, 
2010. 117(2 Suppl): p. S5-10. 
21. Braaten, K.P. and M.R. Laufer, Human Papillomavirus (HPV), HPV-Related Disease, and 
the HPV Vaccine. Rev Obstet Gynecol, 2008. 1(1): p. 2-10. 
22. Yanofsky, V.R., R.V. Patel, and G. Goldenberg, Genital warts: a comprehensive review. 




23. Couturier, J., X. Sastre-Garau, S. Schneider-Maunoury, A. Labib, and G. Orth, Integration 
of papillomavirus DNA near myc genes in genital carcinomas and its consequences for 
proto-oncogene expression. Journal of Virology, 1991. 65(8): p. 4534. 
24. Choo, K.-B., C.-C. Pan, and S.-H. Han, Integration of human papillomavirus type 16 into 
cellular DNA of cervical carcinoma: Preferential deletion of the E2 gene and invariable 
retention of the long control region and the E6/E7 open reading frames. Virology, 1987. 
161(1): p. 259-261. 
25. Münger, K., J.R. Basile, S. Duensing, A. Eichten, S.L. Gonzalez, M. Grace, and V.L. 
Zacny, Biological activities and molecular targets of the human papillomavirus E7 
oncoprotein. Oncogene, 2001. 20(54): p. 7888-7898. 
26. Thaiss, C.A., V. Semmling, L. Franken, H. Wagner, and C. Kurts, Chemokines: A New 
Dendritic Cell Signal for T Cell Activation. Frontiers in Immunology, 2011. 2: p. 31. 
27. Stanley, M., Immune responses to human papillomavirus. Vaccine, 2006. 24: p. S16-S22. 
28. Stanley, M., Immunobiology of HPV and HPV vaccines. Gynecologic Oncology, 2008. 
109(2, Supplement): p. S15-S21. 
29. Le Bon, A. and D.F. Tough, Links between innate and adaptive immunity via type I 
interferon. Current Opinion in Immunology, 2002. 14(4): p. 432-436. 
30. Pett, M. and N. Coleman, Integration of high‐risk human papillomavirus: a key event in 
cervical carcinogenesis? The Journal of Pathology: A Journal of the Pathological Society 
of Great Britain and Ireland, 2007. 212(4): p. 356-367. 
31. Kobayashi, A., R.M. Greenblatt, K. Anastos, H. Minkoff, L.S. Massad, M. Young, A.M. 
Levine, T.M. Darragh, V. Weinberg, and K.K. Smith-McCune, Functional attributes of 
mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer 
research, 2004. 64(18): p. 6766-6774. 
32. Parkin, D.M. and F. Bray, The burden of HPV-related cancers. Vaccine, 2006. 24: p. S11-
S25. 
33. Parikh, S., P. Brennan, and P. Boffetta, Meta-analysis of social inequality and the risk of 
cervical cancer. Int J Cancer, 2003. 105(5): p. 687-91. 
34. Department of Health and Human Services, C.f.D.C.a.P., and National Cancer Institute, 
U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, 
based on 2019 submission data (1999-2017). 2020. 
35. Hirth, J., Disparities in HPV vaccination rates and HPV prevalence in the United States: 
a review of the literature. Human vaccines & immunotherapeutics, 2019. 15(1): p. 146-
155. 
36. Gardasil 9--a broader HPV vaccine. Med Lett Drugs Ther, 2015. 57(1465): p. 47-8. 
37. Lehtinen, M., J. Paavonen, C.M. Wheeler, U. Jaisamrarn, S.M. Garland, X. Castellsagué, 
S.R. Skinner, D. Apter, P. Naud, J. Salmerón, S.N. Chow, H. Kitchener, J.C. Teixeira, J. 
Hedrick, G. Limson, A. Szarewski, B. Romanowski, F.Y. Aoki, T.F. Schwarz, W.A. Poppe, 
N.S. De Carvalho, M.J. Germar, K. Peters, A. Mindel, P. De Sutter, F.X. Bosch, M.P. 
David, D. Descamps, F. Struyf, and G. Dubin, Overall efficacy of HPV-16/18 AS04-




end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol, 
2012. 13(1): p. 89-99. 
38. de Martel, C., M. Plummer, J. Vignat, and S. Franceschi, Worldwide burden of cancer 
attributable to HPV by site, country and HPV type. Int J Cancer, 2017. 141(4): p. 664-
670. 
39. Maxwell, J.H., J.R. Grandis, and R.L. Ferris, HPV-Associated Head and Neck Cancer: 
Unique Features of Epidemiology and Clinical Management. Annu Rev Med, 2016. 67: 
p. 91-101. 
40. Stanley, M., HPV vaccination in boys and men. Hum Vaccin Immunother, 2014. 10(7): p. 
2109-11. 
41. De Vincenzo, R., C. Ricci, C. Conte, and G. Scambia, HPV vaccine cross-protection: 
Highlights on additional clinical benefit. Gynecol Oncol, 2013. 130(3): p. 642-51. 
42. Safaeian, M., J.N. Sampson, Y. Pan, C. Porras, T.J. Kemp, R. Herrero, W. Quint, L.J. 
van Doorn, J. Schussler, and D.R. Lowy, Durability of protection afforded by fewer doses 
of the HPV16/18 vaccine: the CVT trial. JNCI: Journal of the National Cancer Institute, 
2018. 110(2): p. 205-212. 
43. Herrero, R., S. Wacholder, A.C. Rodríguez, D. Solomon, P. González, A.R. Kreimer, C. 
Porras, J. Schussler, S. Jiménez, M.E. Sherman, W. Quint, J.T. Schiller, D.R. Lowy, M. 
Schiffman, and A. Hildesheim, Prevention of persistent human papillomavirus infection 
by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, 
Costa Rica. Cancer Discov, 2011. 1(5): p. 408-19. 
44. Conway, E.L., K.C. Farmer, W.J. Lynch, G.L. Rees, G. Wain, and J. Adams, Quality of 
life valuations of HPV-associated cancer health states by the general population. Sexually 
transmitted infections, 2012. 88(7): p. 517-521. 
45. Kiellberg Larsen, H., K. Kofoed, and C. Sand, [The disease burden of human 
papillomavirus in men is substantial and can potentially be prevented]. Ugeskr Laeger, 
2013. 175(6): p. 349-53. 
46. Forman, D., C. de Martel, C.J. Lacey, I. Soerjomataram, J. Lortet-Tieulent, L. Bruni, J. 
Vignat, J. Ferlay, F. Bray, M. Plummer, and S. Franceschi, Global burden of human 
papillomavirus and related diseases. Vaccine, 2012. 30 Suppl 5: p. F12-23. 
47. Gao, P. and J. Zheng, High-risk HPV E5-induced cell fusion: a critical initiating event in 
the early stage of HPV-associated cervical cancer. Virology Journal, 2010. 7(1): p. 238. 
48. Lyford-Pike, S., S. Peng, G.D. Young, J.M. Taube, W.H. Westra, B. Akpeng, T.C. Bruno, 
J.D. Richmon, H. Wang, J.A. Bishop, L. Chen, C.G. Drake, S.L. Topalian, D.M. Pardoll, 
and S.I. Pai, Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of 
HPV-associated head and neck squamous cell carcinoma. Cancer Res, 2013. 73(6): p. 
1733-41. 
49. Sharpe, A.H. and G.J. Freeman, The B7-CD28 superfamily. Nat Rev Immunol, 2002. 
2(2): p. 116-26. 
50. Fakhr, E., Ž. Modic, and A. Cid-Arregui, Recent developments in immunotherapy of 




51. Santin, A.D., S. Bellone, M. Palmieri, A. Ravaggi, C. Romani, R. Tassi, J.J. Roman, A. 
Burnett, S. Pecorelli, and M.J. Cannon, HPV16/18 E7-pulsed dendritic cell vaccination in 
cervical cancer patients with recurrent disease refractory to standard treatment 
modalities. Gynecol Oncol, 2006. 100(3): p. 469-78. 
52. Ferrara, A., M. Nonn, P. Sehr, C. Schreckenberger, M. Pawlita, M. Dürst, A. Schneider, 
and A.M. Kaufmann, Dendritic cell-based tumor vaccine for cervical cancer II: results of 
a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol, 2003. 129(9): p. 
521-30. 
53. Kang, T.H., J.H. Lee, H.C. Bae, K.H. Noh, J.H. Kim, C.K. Song, B.C. Shin, C.-F. Hung, 
T.-C. Wu, and J.-S. Park, Enhancement of dendritic cell-based vaccine potency by 
targeting antigen to endosomal/lysosomal compartments. Immunology letters, 2006. 
106(2): p. 126-134. 
54. Doran, S.L., S. Stevanović, S. Adhikary, J.J. Gartner, L. Jia, M.L.M. Kwong, W.C. Faquin, 
S.M. Hewitt, R.M. Sherry, J.C. Yang, S.A. Rosenberg, and C.S. Hinrichs, T-Cell Receptor 
Gene Therapy for Human Papillomavirus–Associated Epithelial Cancers: A First-in-
Human, Phase I/II Study. Journal of Clinical Oncology, 2019. 37(30): p. 2759-2768. 
55. Kirtane, K., E. Massarelli, G.J. Hanna, C.A. Klebanoff, G. Blumenschein, M.R. Bishop, S. 
Lee, J. Niu, S. Adhikary, S.H. Astrow, K. Rodriguez, R. Chu, and A.S. Jung, KITE-439: A 
phase I study of HPV16 E7 T cell receptor-engineered T cells in patients with 
relapsed/refractory HPV16-positive cancers. Journal of Clinical Oncology, 2020. 
38(15_suppl): p. TPS3149-TPS3149. 
56. Le Tourneau, C., J.-P. Delord, P. Cassier, D. Loirat, A. Tavernaro, B. Bastien, and K. 
Bendjama, Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-
vaccine, and Avelumab in patients with recurrent/metastatic (R/M) HPV-16+ cancers. 
Annals of Oncology, 2019. 30: p. v494-v495. 
57. Brun, J.-L., V. Dalstein, J. Leveque, P. Mathevet, P. Raulic, J.-J. Baldauf, S. Scholl, B. 
Huynh, S. Douvier, and D. Riethmuller, Regression of high-grade cervical intraepithelial 
neoplasia with TG4001 targeted immunotherapy. American journal of obstetrics and 
gynecology, 2011. 204(2): p. 169. e1-169. e8. 
58. Gunn, G.R., A. Zubair, C. Peters, Z.-K. Pan, T.-C. Wu, and Y. Paterson, Two Listeria 
monocytogenes vaccine vectors that express different molecular forms of human 
papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that 
correlates with their ability to induce regression of established tumors immortalized by 
HPV-16. The Journal of Immunology, 2001. 167(11): p. 6471-6479. 
59. Trimble, C.L., S. Peng, F. Kos, P. Gravitt, R. Viscidi, E. Sugar, D. Pardoll, and T. Wu, A 
phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial 
neoplasia 2/3. Clinical Cancer Research, 2009. 15(1): p. 361-367. 
60. Pellom, S.T., C.S. Rumfield, Y.M. Morillon, N. Roller, D. Brough, H. Sabzevari, J. Greiner, 
J. Schlom, and C. Jochems, Anti-tumor efficacy and immune responses induced by a 
novel therapeutic HPV-specific gorilla adenovirus off-the-shelf immunotherapeutic 
(PRGN-2009). 2020, Am Assoc Immnol. 
61. Ura, T., K. Okuda, and M. Shimada, Developments in Viral Vector-Based Vaccines. 




62. Ginaldi, L., M.F. Loreto, M.P. Corsi, M. Modesti, and M. De Martinis, Immunosenescence 
and infectious diseases. Microbes Infect, 2001. 3(10): p. 851-7. 
63. Liu, W., H. Tang, L. Li, X. Wang, Z. Yu, and J. Li, Peptide-based therapeutic cancer 
vaccine: Current trends in clinical application. Cell Proliferation, 2021. 54(5): p. e13025. 
64. Su, J.-H., A. Wu, E. Scotney, B. Ma, A. Monie, C.-F. Hung, and T.-C. Wu, Immunotherapy 
for cervical cancer. BioDrugs, 2010. 24(2): p. 109-129. 
65. van Poelgeest, M.I.E., M.J.P. Welters, E.M.G. van Esch, L.F.M. Stynenbosch, G. 
Kerpershoek, E.L. van Persijn van Meerten, M. van den Hende, M.J.G. Löwik, D.M.A. 
Berends-van der Meer, L.M. Fathers, A.R.P.M. Valentijn, J. Oostendorp, G.J. Fleuren, 
C.J.M. Melief, G.G. Kenter, and S.H. van der Burg, HPV16 synthetic long peptide 
(HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced 
gynecological carcinoma, a phase II trial. Journal of translational medicine, 2013. 11: p. 
88-88. 
66. Schreckenberger, C. and A.M. Kaufmann, Vaccination strategies for the treatment and 
prevention of cervical cancer. Current opinion in oncology, 2004. 16(5): p. 485-491. 
67. Shi, W., P. Bu, J. Liu, A. Polack, S. Fisher, and L. Qiao, Human papillomavirus type 16 
E7 DNA vaccine: mutation in the open reading frame of E7 enhances specific cytotoxic 
T-lymphocyte induction and antitumor activity. Journal of virology, 1999. 73(9): p. 7877-
7881. 
68. Liu, M.A., Vaccine developments. Nature medicine, 1998. 4(5): p. 515-519. 
69. Ohlschläger, P., M. Pes, W. Osen, M. Dürst, A. Schneider, L. Gissmann, and A.M. 
Kaufmann, An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine 
candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. Vaccine, 
2006. 24(15): p. 2880-93. 
70. Trimble, C.L., S. Peng, F. Kos, P. Gravitt, R. Viscidi, E. Sugar, D. Pardoll, and T.C. Wu, 
A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial 
neoplasia 2/3. Clin Cancer Res, 2009. 15(1): p. 361-7. 
71. Ding, W., Z. Hu, D. Zhu, X. Jiang, L. Yu, X. Wang, C. Zhang, L. Wang, T. Ji, and K. Li, 
Zinc finger nucleases targeting the human papillomavirus E7 oncogene induce E7 
disruption and a transformed phenotype in HPV16/18-positive cervical cancer cells. 
Clinical cancer research, 2014. 20(24): p. 6495-6503. 
72. Hu, Z., W. Ding, D. Zhu, L. Yu, X. Jiang, X. Wang, C. Zhang, L. Wang, T. Ji, and D. Liu, 
TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical 
malignancy. The Journal of clinical investigation, 2015. 125(1): p. 425-436. 
73. Da Silva, D.M., J.G. Skeate, E. Chavez-Juan, K.P. Lühen, J.-M. Wu, C.-M. Wu, W.M. 
Kast, and K. Hwang, Therapeutic efficacy of a human papillomavirus type 16 E7 bacterial 
exotoxin fusion protein adjuvanted with CpG or GPI-0100 in a preclinical mouse model 
for HPV-associated disease. Vaccine, 2019. 37(22): p. 2915-2924. 
74. Garza-Morales, R., J.J. Perez-Trujillo, E. Martinez-Jaramillo, O. Saucedo-Cardenas, M.J. 
Loera-Arias, A. Garcia-Garcia, H. Rodriguez-Rocha, E. Yolcu, H. Shirwan, J.G. Gomez-
Gutierrez, and R. Montes-de-Oca-Luna, A DNA Vaccine Encoding SA-4-1BBL Fused to 
HPV-16 E7 Antigen Has Prophylactic and Therapeutic Efficacy in a Cervical Cancer 




75. Liao, J.B., J. Publicover, J.K. Rose, and D. DiMaio, Single-Dose, Therapeutic Vaccination 
of Mice with Vesicular Stomatitis Virus Expressing Human Papillomavirus Type 16 E7 
Protein. Clinical and Vaccine Immunology, 2008. 15(5): p. 817-824. 
76. Lee, S.Y., T.H. Kang, J. Knoff, Z. Huang, R.S. Soong, R.D. Alvarez, C.F. Hung, and T.C. 
Wu, Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin 
enhances HPV-specific antitumor effects. Cancer Immunol Immunother, 2013. 62(7): p. 
1175-85. 
77. McDermott, M.R. and J. Bienenstock, Evidence for a common mucosal immunologic 
system. I. Migration of B immunoblasts into intestinal, respiratory, and genital tissues. J 
Immunol, 1979. 122(5): p. 1892-8. 
78. Janeway CA Jr, T.P., Walport M, et al., The mucosal immune system, in Immunobiology: 
The Immune System in Health and Disease. 2001, Garland Science: New York. 
79. Cesta, M.F., Normal structure, function, and histology of mucosa-associated lymphoid 
tissue. Toxicol Pathol, 2006. 34(5): p. 599-608. 
80. Holmgren, J. and C. Czerkinsky, Mucosal immunity and vaccines. Nature Medicine, 2005. 
11(4): p. S45-S53. 
81. Westwood, J.A., T.C. Potdevin Hunnam, H.J. Pegram, R.J. Hicks, P.K. Darcy, and M.H. 
Kershaw, Routes of delivery for CpG and anti-CD137 for the treatment of orthotopic 
kidney tumors in mice. PLoS One, 2014. 9(5): p. e95847. 
82. Kozlowski, P.A., S. Cu-Uvin, M.R. Neutra, and T.P. Flanigan, Comparison of the oral, 
rectal, and vaginal immunization routes for induction of antibodies in rectal and genital 
tract secretions of women. Infection and immunity, 1997. 65(4): p. 1387-1394. 
83. Sultan, H., T. Kumai, T. Nagato, J. Wu, A.M. Salazar, and E. Celis, The route of 
administration dictates the immunogenicity of peptide-based cancer vaccines in mice. 
Cancer Immunol Immunother, 2019. 68(3): p. 455-466. 
84. Nizard, M., M.O. Diniz, H. Roussel, T. Tran, L.C.S. Ferreira, C. Badoual, and E. Tartour, 
Mucosal vaccines. Human Vaccines & Immunotherapeutics, 2014. 10(8): p. 2175-2187. 
85. Bandyopadhyay, A.S., J. Garon, K. Seib, and W.A. Orenstein, Polio vaccination: past, 
present and future. Future Microbiol, 2015. 10(5): p. 791-808. 
86. De Bernardis, F., M. Boccanera, D. Adriani, A. Girolamo, and A. Cassone, Intravaginal 
and Intranasal Immunizations Are Equally Effective in Inducing Vaginal Antibodies and 
Conferring Protection against Vaginal Candidiasis. Infection and Immunity, 2002. 70(5): 
p. 2725. 
87. Weaver, E.A., P.N. Nehete, B.P. Nehete, G. Yang, S.J. Buchl, P.W. Hanley, D. Palmer, 
D.C. Montefiori, G. Ferrari, P. Ng, K.J. Sastry, and M.A. Barry, Comparison of Systemic 
and Mucosal Immunization with Helper-Dependent Adenoviruses for Vaccination against 
Mucosal Challenge with SHIV. PLoS ONE, 2013. 8(7): p. e67574. 
88. Shakya, A.K., M.Y.E. Chowdhury, W. Tao, and H.S. Gill, Mucosal vaccine delivery: 
Current state and a pediatric perspective. Journal of Controlled Release, 2016. 240: p. 
394-413. 
89. Lycke, N., Recent progress in mucosal vaccine development: potential and limitations. 




90. Sandoval, F., M. Terme, M. Nizard, C. Badoual, M.-F. Bureau, L. Freyburger, O. Clement, 
E. Marcheteau, A. Gey, G. Fraisse, C. Bouguin, N. Merillon, E. Dransart, T. Tran, F. 
Quintin-Colonna, G. Autret, M. Thiebaud, M. Suleman, S. Riffault, T.-C. Wu, O. Launay, 
C. Danel, J. Taieb, J. Richardson, L. Zitvogel, W.H. Fridman, L. Johannes, and E. Tartour, 
Mucosal imprinting of vaccine-induced CD8⁺ T cells is crucial to inhibit the growth of 
mucosal tumors. Science translational medicine, 2013. 5(172): p. 172ra20-172ra20. 
91. Johansson-Lindbom, B., M. Svensson, O. Pabst, C. Palmqvist, G. Marquez, R. Förster, 
and W.W. Agace, Functional specialization of gut CD103+ dendritic cells in the regulation 
of tissue-selective T cell homing. The Journal of experimental medicine, 2005. 202(8): p. 
1063-1073. 
92. Mutsch, M., W. Zhou, P. Rhodes, M. Bopp, R.T. Chen, T. Linder, C. Spyr, and R. Steffen, 
Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in 
Switzerland. New England journal of medicine, 2004. 350(9): p. 896-903. 
93. Hagiwara, Y., T. Iwasaki, H. Asanuma, Y. Sato, T. Sata, C. Aizawa, T. Kurata, and S. 
Tamura, Effects of intranasal administration of cholera toxin (or Escherichia coli heat-
labile enterotoxin) B subunits supplemented with a trace amount of the holotoxin on the 
brain. Vaccine, 2001. 19(13-14): p. 1652-60. 
94. Pesce, I., E. Monaci, A. Muzzi, E. Tritto, S. Tavarini, S. Nuti, E. De Gregorio, and A. Wack, 
Intranasal administration of CpG induces a rapid and transient cytokine response 
followed by dendritic and natural killer cell activation and recruitment in the mouse lung. 
Journal of innate immunity, 2010. 2(2): p. 144-159. 
95. Huang, C.F., T.C. Wu, Y.H. Chu, K.S. Hwang, C.C. Wang, and H.J. Peng, Effect of 
neonatal sublingual vaccination with native or denatured ovalbumin and adjuvant CpG or 
cholera toxin on systemic and mucosal immunity in mice. Scandinavian journal of 
immunology, 2008. 68(5): p. 502-510. 
96. Didierlaurent, A.M., S. Morel, L. Lockman, S.L. Giannini, M. Bisteau, H. Carlsen, A. 
Kielland, O. Vosters, N. Vanderheyde, and F. Schiavetti, AS04, an aluminum salt-and 
TLR4 agonist-based adjuvant system, induces a transient localized innate immune 
response leading to enhanced adaptive immunity. The Journal of immunology, 2009. 
183(10): p. 6186-6197. 
97. Arias, M.A., G.A. Van Roey, J.S. Tregoning, M. Moutaftsi, R.N. Coler, H.P. Windish, S.G. 
Reed, D. Carter, and R.J. Shattock, Glucopyranosyl lipid adjuvant (GLA), a synthetic 
TLR4 agonist, promotes potent systemic and mucosal responses to intranasal 
immunization with HIVgp140. PloS one, 2012. 7(7): p. e41144. 
98. Rhee, J.H., S.E. Lee, and S.Y. Kim, Mucosal vaccine adjuvants update. Clinical and 
experimental vaccine research, 2012. 1(1): p. 50-63. 
99. Aoshi, T., Modes of Action for Mucosal Vaccine Adjuvants. Viral immunology, 2017. 
30(6): p. 463-470. 
100. Sullivan, B.A. and M. Kronenberg, Activation or anergy: NKT cells are stunned by alpha-
galactosylceramide. The Journal of clinical investigation, 2005. 115(9): p. 2328-2329. 
101. Kamijuku, H., Y. Nagata, X. Jiang, T. Ichinohe, T. Tashiro, K. Mori, M. Taniguchi, K. Hase, 
H. Ohno, T. Shimaoka, S. Yonehara, T. Odagiri, M. Tashiro, T. Sata, H. Hasegawa, and 




galactosylceramide, which can induce cross-protection against influenza viruses. 
Mucosal Immunol, 2008. 1(3): p. 208-218. 
102. Nieda, M., M. Okai, A. Tazbirkova, H. Lin, A. Yamaura, K. Ide, R. Abraham, T. Juji, D.J. 
Macfarlane, and A.J. Nicol, Therapeutic activation of Valpha24+Vbeta11+ NKT cells in 
human subjects results in highly coordinated secondary activation of acquired and innate 
immunity. Blood, 2004. 103(2): p. 383-9. 
103. Ishikawa, A., S. Motohashi, E. Ishikawa, H. Fuchida, K. Higashino, M. Otsuji, T. Iizasa, T. 
Nakayama, M. Taniguchi, and T. Fujisawa, A phase I study of alpha-galactosylceramide 
(KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell 
lung cancer. Clin Cancer Res, 2005. 11(5): p. 1910-7. 
104. Youn, H.-J., S.-Y. Ko, K.-A. Lee, H.-J. Ko, Y.-S. Lee, K. Fujihashi, P.N. Boyaka, S.-H. 
Kim, T. Horimoto, M.-N. Kweon, and C.-Y. Kang, A single intranasal immunization with 
inactivated influenza virus and α-galactosylceramide induces long-term protective 
immunity without redirecting antigen to the central nervous system. Vaccine, 2007. 
25(28): p. 5189-5198. 
105. Courtney, A.N., P.N. Nehete, B.P. Nehete, P. Thapa, D. Zhou, and K.J. Sastry, Alpha-
galactosylceramide is an effective mucosal adjuvant for repeated intranasal or oral 
delivery of HIV peptide antigens. Vaccine, 2009. 27(25–26): p. 3335-3341. 
106. Khan, A., S. Singh, G. Galvan, C. Jagannath, and K.J. Sastry, Prophylactic Sublingual 
Immunization with Mycobacterium tuberculosis Subunit Vaccine Incorporating the Natural 
Killer T Cell Agonist Alpha-Galactosylceramide Enhances Protective Immunity to Limit 
Pulmonary and Extra-Pulmonary Bacterial Burden in Mice. Vaccines (Basel), 2017. 5(4). 
107. Courtney, A.N., P. Thapa, S. Singh, A.M. Wishahy, D. Zhou, and J. Sastry, Intranasal but 
not intravenous delivery of the adjuvant α-galactosylceramide permits repeated 
stimulation of natural killer T cells in the lung. European journal of immunology, 2011. 
41(11): p. 3312-3322. 
108. Giaccone, G., C.J.A. Punt, Y. Ando, R. Ruijter, N. Nishi, M. Peters, B.M.E. von Blomberg, 
R.J. Scheper, H.J.J. van der Vliet, A.J.M. van den Eertwegh, M. Roelvink, J. Beijnen, H. 
Zwierzina, and H.M. Pinedo, A Phase I Study of the Natural Killer T-Cell Ligand α-
Galactosylceramide (KRN7000) in Patients with Solid Tumors. Clinical Cancer Research, 
2002. 8(12): p. 3702-3709. 
109. Gableh, F., M. Saeidi, S. Hemati, K. Hamdi, H. Soleimanjahi, A. Gorji, and A. Ghaemi, 
Combination of the toll like receptor agonist and alpha-Galactosylceramide as an efficient 
adjuvant for cancer vaccine. J Biomed Sci, 2016. 23: p. 16. 
110. Ando, T., H. Ito, H. Ohtaki, and M. Seishima, Toll-like Receptor agonists and alpha-
galactosylceramide synergistically enhance the production of interferon-gamma in murine 
splenocytes. Sci. Rep., 2013. 3. 
111. Gableh, F., M. Saeidi, S. Hemati, K. Hamdi, H. Soleimanjahi, A. Gorji, and A. Ghaemi, 
Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient 
adjuvant for cancer vaccine. Journal of Biomedical Science, 2016. 23(1): p. 16. 
112. Sarkar, A.K., G. Tortolero-Luna, M. Follen, and K.J. Sastry, Inverse correlation of cellular 




HPV-16 with recurrence of cervical intraepithelial neoplasia in a cross-sectional study. 
Gynecologic Oncology, 2005. 99(3, Supplement): p. S251-S261. 
113. Decrausaz, L., A.R. Goncalves, S. Domingos-Pereira, C. Pythoud, J.C. Stehle, J. Schiller, 
P. Jichlinski, and D. Nardelli-Haefliger, A novel mucosal orthotopic murine model of 
human papillomavirus-associated genital cancers. Int J Cancer, 2011. 128(9): p. 2105-
13. 
114. Bartkowiak, T., S. Singh, G. Yang, G. Galvan, D. Haria, M. Ai, J.P. Allison, K.J. Sastry, 
and M.A. Curran, Unique potential of 4-1BB agonist antibody to promote durable 
regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. Proc Natl 
Acad Sci U S A, 2015. 112(38): p. E5290-9. 
115. Dorta-Estremera, S., R.L. Chin, G. Sierra, C. Nicholas, A.V. Yanamandra, S.M.K. 
Nookala, G. Yang, S. Singh, M.A. Curran, and K.J. Sastry, Mucosal HPV E6/E7 Peptide 
Vaccination in Combination with Immune Checkpoint Modulation Induces Regression of 
HPV(+) Oral Cancers. Cancer Res, 2018. 78(18): p. 5327-5339. 
116. Sierra, G., S. Dorta-Estremera, V.L. Hegde, S.M.K. Nookala, A.V. Yanamandra, and K.J. 
Sastry, Intranasal Therapeutic Peptide Vaccine Promotes Efficient Induction and 
Trafficking of Cytotoxic T Cell Response for the Clearance of HPV Vaginal Tumors. 
Vaccines (Basel), 2020. 8(2). 
117. Singh, S., K.S. Schluns, G. Yang, S.M. Anthony, M.A. Barry, and K.J. Sastry, Intranasal 
Vaccination Affords Localization and Persistence of Antigen-Specific CD8(+) T 
Lymphocytes in the Female Reproductive Tract. Vaccines (Basel), 2016. 4(1). 
118. Dubrot, J., F. Milheiro, C. Alfaro, A. Palazon, I. Martinez-Forero, J.L. Perez-Gracia, A. 
Morales-Kastresana, J.L. Romero-Trevejo, M.C. Ochoa, S. Hervas-Stubbs, J. Prieto, M. 
Jure-Kunkel, L. Chen, and I. Melero, Treatment with anti-CD137 mAbs causes intense 
accumulations of liver T cells without selective antitumor immunotherapeutic effects in 
this organ. Cancer Immunol Immunother, 2010. 59(8): p. 1223-33. 
119. Melero, I., D. Hirschhorn-Cymerman, A. Morales-Kastresana, M.F. Sanmamed, and J.D. 
Wolchok, Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin 
Cancer Res, 2013. 19(5): p. 1044-53. 
120. Niu, L., S. Strahotin, B. Hewes, B. Zhang, Y. Zhang, D. Archer, T. Spencer, D. Dillehay, 
B. Kwon, L. Chen, A.T. Vella, and R.S. Mittler, Cytokine-mediated disruption of 
lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and 
thrombocytopenia in anti-CD137-treated mice. J Immunol, 2007. 178(7): p. 4194-213. 
121. Fujii , S.-i., K. Shimizu , C. Smith , L. Bonifaz , and R.M. Steinman Activation of Natural 
Killer T Cells by α-Galactosylceramide Rapidly Induces the Full Maturation of Dendritic 
Cells In Vivo and Thereby Acts as an Adjuvant for Combined CD4 and CD8 T Cell 
Immunity to a Coadministered Protein. Journal of Experimental Medicine, 2003. 198(2): 
p. 267-279. 
122. Semmling, V., V. Lukacs-Kornek, C.A. Thaiss, T. Quast, K. Hochheiser, U. Panzer, J. 
Rossjohn, P. Perlmutter, J. Cao, D.I. Godfrey, P.B. Savage, P.A. Knolle, W. Kolanus, I. 
Forster, and C. Kurts, Alternative cross-priming through CCL17-CCR4-mediated 




123. Galon, J., A. Costes, F. Sanchez-Cabo, A. Kirilovsky, B. Mlecnik, C. Lagorce-Pagès, M. 
Tosolini, M. Camus, A. Berger, P. Wind, F. Zinzindohoué, P. Bruneval, P.-H. Cugnenc, 
Z. Trajanoski, W.-H. Fridman, and F. Pagès, Type, Density, and Location of Immune Cells 
Within Human Colorectal Tumors Predict Clinical Outcome. Science, 2006. 313(5795): 
p. 1960. 
124. Hwang, W.-T., S.F. Adams, E. Tahirovic, I.S. Hagemann, and G. Coukos, Prognostic 
significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis. Gynecologic 
Oncology, 2012. 124(2): p. 192-198. 
125. Piersma, S.J., E.S. Jordanova, M.I.E. Van Poelgeest, K.M.C. Kwappenberg, J.M. Van 
Der Hulst, J.W. Drijfhout, C.J.M. Melief, G.G. Kenter, G.J. Fleuren, R. Offringa, and S.H. 
Van Der Burg, High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is 
associated with the absence of lymph node metastases in patients with large early-stage 
cervical cancer. Cancer Research, 2007. 67(1): p. 354-361. 
126. Bremnes, R.M., K. Al-Shibli, T. Donnem, R. Sirera, S. Al-Saad, S. Andersen, H. Stenvold, 
C. Camps, and L.-T. Busund, The Role of Tumor-Infiltrating Immune Cells and Chronic 
Inflammation at the Tumor Site on Cancer Development, Progression, and Prognosis: 
Emphasis on Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011. 6(4): p. 
824-833. 
127. Touat, M., D. Talmasov, D. Ricard, and D. Psimaras, Neurological toxicities associated 
with immune-checkpoint inhibitors. Curr Opin Neurol, 2017. 30(6): p. 659-668. 
128. Puzanov, I., A. Diab, K. Abdallah, C.O. Bingham, 3rd, C. Brogdon, R. Dadu, L. Hamad, 
S. Kim, M.E. Lacouture, N.R. LeBoeuf, D. Lenihan, C. Onofrei, V. Shannon, R. Sharma, 
A.W. Silk, D. Skondra, M.E. Suarez-Almazor, Y. Wang, K. Wiley, H.L. Kaufman, M.S. 
Ernstoff, and G. Society for Immunotherapy of Cancer Toxicity Management Working, 
Managing toxicities associated with immune checkpoint inhibitors: consensus 
recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity 
Management Working Group. Journal for immunotherapy of cancer, 2017. 5(1): p. 95-95. 
129. Dubrot, J., F. Milheiro, C. Alfaro, A. Palazón, I. Martinez-Forero, J.L. Perez-Gracia, A. 
Morales-Kastresana, J.L. Romero-Trevejo, M.C. Ochoa, S. Hervás-Stubbs, J. Prieto, M. 
Jure-Kunkel, L. Chen, and I. Melero, Treatment with anti-CD137 mAbs causes intense 
accumulations of liver T cells without selective antitumor immunotherapeutic effects in 
this organ. Cancer Immunol Immunother, 2010. 59(8): p. 1223-33. 
130. Liao, C.-M., M.I. Zimmer, and C.-R. Wang, The functions of type I and type II natural killer 
T cells in inflammatory bowel diseases. Inflammatory bowel diseases, 2013. 19(6): p. 
1330-1338. 
131. Singh, A.K., P. Tripathi, and S.L. Cardell, Type II NKT Cells: An Elusive Population With 
Immunoregulatory Properties. Frontiers in Immunology, 2018. 9(1969). 
132. Zhao, J., X. Weng, S. Bagchi, and C.R. Wang, Polyclonal type II natural killer T cells 
require PLZF and SAP for their development and contribute to CpG-mediated antitumor 
response. Proc Natl Acad Sci U S A, 2014. 111(7): p. 2674-9. 
133. Exley, M.A., S.M.A. Tahir, O. Cheng, A. Shaulov, R. Joyce, D. Avigan, R. Sackstein, and 
S.P. Balk, Cutting Edge: A Major Fraction of Human Bone Marrow Lymphocytes Are Th2-
Like CD1d-Reactive T Cells That Can Suppress Mixed Lymphocyte Responses. The 




134. Li, H., X. Wu, and X. Cheng, Advances in diagnosis and treatment of metastatic cervical 
cancer. Journal of gynecologic oncology, 2016. 27(4): p. e43-e43. 
135. Singh, P., Cervical cancer: aetiology, earlier diagnosis and treatment. Ann Acad Med 
Singapore, 1990. 19(2): p. 255-63. 
136. Printz, C., Women who undergo HPV testing receive earlier detection and treatment of 
cervical precancers. Cancer, 2017. 123(24): p. 4751. 
137. Verma, V., T. Sprave, W. Haque, C.B. Simone, 2nd, J.Y. Chang, J.W. Welsh, and C.R. 
Thomas, Jr., A systematic review of the cost and cost-effectiveness studies of immune 
checkpoint inhibitors. Journal for immunotherapy of cancer, 2018. 6(1): p. 128-128. 
138. Compte, M., S.L. Harwood, I.G. Muñoz, R. Navarro, M. Zonca, G. Perez-Chacon, A. Erce-
Llamazares, N. Merino, A. Tapia-Galisteo, A.M. Cuesta, K. Mikkelsen, E. Caleiras, N. 
Nuñez-Prado, M.A. Aznar, S. Lykkemark, J. Martínez-Torrecuadrada, I. Melero, F.J. 
Blanco, J. Bernardino de la Serna, J.M. Zapata, L. Sanz, and L. Alvarez-Vallina, A tumor-
targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without 
systemic toxicity. Nature Communications, 2018. 9(1): p. 4809. 
139. Qi, X., F. Li, Y. Wu, C. Cheng, P. Han, J. Wang, and X. Yang, Optimization of 4-1BB 
antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity. 
Nature Communications, 2019. 10(1): p. 2141. 
140. Bartkowiak, T., S. Singh, G. Yang, G. Galvan, D. Haria, M. Ai, J.P. Allison, K.J. Sastry, 
and M.A. Curran, Unique potential of 4-1BB agonist antibody to promote durable 
regression of HPV(+) tumors when combined with an E6/E7 peptide vaccine. 
Proceedings of the National Academy of Sciences of the United States of America, 2015. 
112(38): p. E5290-E5299. 
141. Fujii, S.-I., K. Shimizu, C. Smith, L. Bonifaz, and R.M. Steinman, Activation of natural killer 
T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells 
in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a 
coadministered protein. The Journal of experimental medicine, 2003. 198(2): p. 267-279. 
142. Marschner, A., S. Rothenfusser, V. Hornung, D. Prell, A. Krug, M. Kerkmann, D. Wellisch, 
H. Poeck, A. Greinacher, T. Giese, S. Endres, and G. Hartmann, CpG ODN enhance 
antigen-specific NKT cell activation via plasmacytoid dendritic cells. European Journal of 
Immunology, 2005. 35(8): p. 2347-2357. 
143. Suzuki, Y., D. Wakita, K. Chamoto, Y. Narita, T. Tsuji, T. Takeshima, H. Gyobu, Y. 
Kawarada, S. Kondo, S. Akira, H. Katoh, H. Ikeda, and T. Nishimura, Liposome-
Encapsulated CpG Oligodeoxynucleotides as a Potent Adjuvant for Inducing Type 1 
Innate Immunity. Cancer Research, 2004. 64(23): p. 8754. 
144. Shang, B., Y. Liu, S.-j. Jiang, and Y. Liu, Prognostic value of tumor-infiltrating FoxP3+ 
regulatory T cells in cancers: a systematic review and meta-analysis. Scientific reports, 
2015. 5: p. 15179-15179. 
145. Singh, S., G. Yang, S.N. Byrareddy, M.A. Barry, and K.J. Sastry, Natural killer T cell and 
TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 
envelope protein. Vaccine, 2014. 32(51): p. 6934-40. 
146. Hermans, I.F., J.D. Silk, U. Gileadi, S.H. Masri, D. Shepherd, K.J. Farrand, M. Salio, and 




TLR Ligands and Invariant NKT Cells. The Journal of Immunology, 2007. 178(5): p. 2721-
2729. 
147. Osmond, T.L., K.J. Farrand, G.F. Painter, C. Ruedl, T.R. Petersen, and I.F. Hermans, 
Activated NKT Cells Can Condition Different Splenic Dendritic Cell Subsets To Respond 
More Effectively to TLR Engagement and Enhance Cross-Priming. The Journal of 
Immunology, 2015. 195(3): p. 821-831. 
148. Youn, J.-I., S. Nagaraj, M. Collazo, and D.I. Gabrilovich, Subsets of myeloid-derived 
suppressor cells in tumor-bearing mice. Journal of immunology (Baltimore, Md. : 1950), 
2008. 181(8): p. 5791-5802. 
149. Bronte, V., S. Brandau, S.-H. Chen, M.P. Colombo, A.B. Frey, T.F. Greten, S. 
Mandruzzato, P.J. Murray, A. Ochoa, S. Ostrand-Rosenberg, P.C. Rodriguez, A. Sica, V. 
Umansky, R.H. Vonderheide, and D.I. Gabrilovich, Recommendations for myeloid-
derived suppressor cell nomenclature and characterization standards. Nature 
Communications, 2016. 7(1): p. 12150. 
150. Rodríguez, P.C. and A.C. Ochoa, Arginine regulation by myeloid derived suppressor cells 
and tolerance in cancer: mechanisms and therapeutic perspectives. Immunological 
reviews, 2008. 222: p. 180-191. 
151. Fujii, S.-i., K. Shimizu, M. Kronenberg, and R.M. Steinman, Prolonged IFN-γ–producing 
NKT response induced with α-galactosylceramide–loaded DCs. Nature immunology, 
2002. 3(9): p. 867-874. 
152. Parekh, V.V., M.T. Wilson, D. Olivares-Villagómez, A.K. Singh, L. Wu, C.-R. Wang, S. 
Joyce, and L. Van Kaer, Glycolipid antigen induces long-term natural killer T cell anergy 
in mice. The Journal of clinical investigation, 2005. 115(9): p. 2572-2583. 
153. Wang, Y. and S.L. Cardell, The Yin and Yang of invariant Natural Killer T Cells in Tumor 
immunity—Suppression of Tumor immunity in the intestine. Frontiers in immunology, 
2018. 8: p. 1945. 
154. Kato, S., J.A. Berzofsky, and M. Terabe, Possible therapeutic application of targeting type 
II natural killer T cell-mediated suppression of tumor immunity. Frontiers in immunology, 
2018. 9: p. 314. 
155. Walzer, T., M. Bléry, J. Chaix, N. Fuseri, L. Chasson, S.H. Robbins, S. Jaeger, P. André, 
L. Gauthier, L. Daniel, K. Chemin, Y. Morel, M. Dalod, J. Imbert, M. Pierres, A. Moretta, 
F. Romagné, and E. Vivier, Identification, activation, and selective &lt;em&gt;in 
vivo&lt;/em&gt; ablation of mouse NK cells via NKp46. Proceedings of the National 
Academy of Sciences, 2007. 104(9): p. 3384. 
156. Scheuplein, F., D.J. Lamont, M.E. Poynter, J.E. Boyson, D. Serreze, L.K.A. Lundblad, R. 
Mashal, and R. Schaub, Mouse Invariant Monoclonal Antibody NKT14: A Novel Tool to 
Manipulate iNKT Cell Function In Vivo. PloS one, 2015. 10(10): p. e0140729-e0140729. 
157. Neeland, M.R., W. Shi, C. Collignon, N. Taubenheim, E.N.T. Meeusen, A.M. 
Didierlaurent, and M.J. de Veer, The Lymphatic Immune Response Induced by the 
Adjuvant AS01: A Comparison of Intramuscular and Subcutaneous Immunization Routes. 
The Journal of Immunology, 2016. 197(7): p. 2704-2714. 
158. Wei, T., D. Buehler, E. Ward-Shaw, and P.F. Lambert, An Infection-Based Murine Model 




159. van Poelgeest, M.I., M.J. Welters, E.M. van Esch, L.F. Stynenbosch, G. Kerpershoek, 
E.L. van Persijn van Meerten, M. van den Hende, M.J. Löwik, D.M. Berends-van der 
Meer, L.M. Fathers, A.R. Valentijn, J. Oostendorp, G.J. Fleuren, C.J. Melief, G.G. Kenter, 
and S.H. van der Burg, HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy 
of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase 
II trial. J Transl Med, 2013. 11: p. 88. 
160. Kenter, G.G., M.J.P. Welters, A.R.P.M. Valentijn, M.J.G. Lowik, D.M.A. Berends-van der 
Meer, A.P.G. Vloon, F. Essahsah, L.M. Fathers, R. Offringa, J.W. Drijfhout, A.R. 
Wafelman, J. Oostendorp, G.J. Fleuren, S.H. van der Burg, and C.J.M. Melief, 
Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia. New 
England Journal of Medicine, 2009. 361(19): p. 1838-1847. 
161. Massarelli, E., W. William, F. Johnson, M. Kies, R. Ferrarotto, M. Guo, L. Feng, J.J. Lee, 
H. Tran, Y.U. Kim, C. Haymaker, C. Bernatchez, M. Curran, T. Zecchini Barrese, J. 
Rodriguez Canales, I. Wistuba, L. Li, J. Wang, S.H. van der Burg, C.J. Melief, and B. 
Glisson, Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for 
Patients With Incurable Human Papillomavirus 16–Related Cancer: A Phase 2 Clinical 







Gloria Sierra, formally known as Gloria Galván was born to Rodrigo and Maria 
Galván in Hoffman Estates, Illinois.  After moving to Texas and completing her work at 
Royal High School, in Brookshire, Texas in 2009, she entered Texas A&M University in 
College Station, Texas where she had the opportunity to work as an undergraduate 
research assistant under the direction of Dr. James E. Samuel, Ph.D., in the Department 
of Microbial and Molecular Pathogenesis.  She received a Bachelor of Science degree 
in Biology with a minor in Spanish from Texas A&M University in May, 2013, and 
graduated as an Undergraduate Research Scholar where her thesis identified four 
nuclear localized proteins essential for pathogenic replication.  For the next year and a 
half, she worked as the Sales and Operations manager at Adam’s Tree Service, a local 
tree trimming and landscaping company.  In August of 2014 she enrolled at The 
University of Texas MD Anderson Cancer Center UTHealth Graduate School of 
Biomedical Sciences, where she was president of the Association of Minority Biomedical 




7950 N Stadium Dr. #138 
Houston, Texas 77030 
 
